Patent Grant
11311674
The present invention, in some embodiments thereof, relates to a visual user indicator and, more particularly, but not exclusively, to a medicament delivery device used as a user indicator light.
U.S. Pat. No. 8,784,378 discloses “A visual identification coding for a cartridge or cartridge holder for use with a drug delivery device is described. The visual identification coding includes a cartridge containing a drug and a light source located on the cartridge to visually indicate that the correct cartridge has been inserted into the drug delivery device. The light source may be a light emitting diode (LED), a surface mount diode (SMD), or an organic light emitting diode (OLED). A cartridge holder may also be included to receive the cartridge. In another embodiment, the light source may be located on the cartridge holder or a dose setting member.”
U.S. Patent Application Publication no. 2014/0228768 to Eggert discloses “a handheld medical device having a housing, at least one operator activatable button mounted on a surface of the housing, and a light source mounted within the housing below the button and arranged to direct light towards the button. Substantially the whole of the button and the surface of the housing adjacent the button are opaque, save for a narrow strip adjacent the periphery of the button which is non-opaque.”
Additional background art includes International Patent Application Publication no. WO2013173092 to the present inventor.
A medical delivery device having a void for containing a cartridge and at least one window, comprising: a cartridge containing a fluid material, the cartridge including: a light pipe section which acts as a light pipe having an input location; and a light diffusing section optically coupled to the light pipe and aligned with the window when the cartridge is positioned in the void; a light source optically coupled to the cartridge at the input location to the light pipe, such that at least some light from the light source entering at the input location is diffused at the light diffusing section.
A medical delivery device, comprising: a housing defining a void therein for a cartridge and having a window overlapping with at least part of the void; a cartridge containing a fluid material and positioned within the void, the cartridge including: a light pipe section which acts as a light pipe having an input location; and a light diffusing section optically coupled to the light pipe and aligned with the window when the cartridge is positioned in the void; a light source positioned within the housing and optically coupled to the cartridge at the input location to the light pipe, such that at least some light from the light source entering at the input location is diffused at the light diffusing section and exits the housing through the window.
The device according to any of examples 1-2, further comprising a housing defining a void therein for the cartridge and having a window overlapping with at least part of the void; wherein the cartridge is positioned within the void, and the light source is positioned within the housing, such that the light diffused at the light diffusing section exits the housing through the window.
The device according to any of examples 1-3, further comprising a control circuitry having instructions to operate the light source in accordance with an operation status of the medical delivery device.
The device according to any of examples 1-2, wherein the light diffusing section comprises at least one protruding element.
The device according to example 5, wherein the protruding element at least partially surrounds a circumference of the cartridge.
The device according to example 5, wherein the protruding element extends at an angle beyond a tangent to a wall of the cartridge.
The device according to example 1, wherein the light diffusing section comprises a surface area having increased surface roughness.
The device according to example 8, wherein the surface area diffuses the light in an even distribution.
The device according to example 8, wherein the surface area is sized to distribute the light over an area at least twice an area defined by a surface area of the light source.
The device according to example 1, wherein the light diffusing section comprises at least one bulge.
The device according to example 1, wherein the light diffusing section comprises at least one slit.
The device according to example 1, wherein the cartridge further comprises indicia.
The device according to example 13, wherein the light diffusing section is positioned in proximity to the indicia, such that the light pipe and the indicia are viewable from a single viewing direction.
The device according to example 1, wherein the light source is provided at a number having a range of 2 to 7 light sources.
The device according to example 1, wherein the light source is provided at a number having a range of 3 to 6 light sources.
The device according to example 16, having a plurality of the input locations and a plurality of the light diffusing sections, each of which is coupled to each of the input locations.
The device according to example 17, wherein each of the input locations and its associated light diffusing section are optically coupled to single light source of the light sources.
A method for indicating a user about a state of a medical delivery device comprising: optically coupling at least one light source with a cartridge containing a fluid material and having a light input location; optically coupling through the cartridge a light diffusing section to the light input location; positioning the at least one light source and the cartridge in a housing having a window, such that the light diffusing section is aligned with the window; operating the at least one light source in accordance with a state of the medical delivery device.
The method according to example 19, wherein the state of the medical delivery device comprises an ongoing delivery state.
The method according to example 19, wherein the state of the medical delivery device comprises a stop delivery state.
The method according to example 19, wherein the state of the medical delivery device comprises an on or off state.
The method according to example 19, wherein the state of the medical delivery device comprises device malfunction state.
The method according to example 19, wherein the state of the medical delivery device comprises an inventory status of the fluid material.
The method according to example 19, wherein the operating the at least one light source comprises turning the light source in a continuous manner.
The method according to example 19, wherein the operating the at least one light source comprises turning the light source on in an intermittent manner.
The method according to example 26, wherein the operating the at least one light source comprises changing a frequency of the intermittent manner.
The method according to example 19, wherein the operating the at least one light source comprises turning the light source off.
The method according to example 19, wherein the operating the at least one light source comprises changing the light source color.
A process of manufacturing a medical delivery device, comprising: molding a cartridge to include: a transparent section which acts as a light pipe having an input location; and a light diffusing section optically coupled to the light pipe; filling the cartridge with a fluid material; providing a housing defining a void therein for a cartridge and having a window overlapping with at least part of the void; positioning the cartridge within the void such that the light diffusing section is aligned with the window; positioning at least one light source within the housing and optically coupling the at least one light source to the light pipe through the input location, such that at least some light from the light source entering at the light pipe input is diffused at the light diffusing section and exits the housing through the window.
The process according to example 30, wherein the molding comprises using Crystal Zenith.
The process according to any of examples 30-31, further comprising operatively coupling the at least one light source with a control circuitry.
The process according to example 32, further comprising programming the control circuitry to turn on or turn off the at least one light source according to an operation state of the device.
The process according to example 32, further comprising programming the control circuitry to adjust a light generated by the at least one light source according to an inventory status of the fluid material.
The process according to any of examples 30-34, further comprising molding the light diffusing section in a position allowing view of a physical indicator of an inventory state of the fluid material.
The process according to example 35, wherein the physical indicator comprises a fluid level of the fluid material.
The process according to example 35, wherein the physical indicator comprises indicia markings.
The process according to example 35, wherein the physical indicator comprises a cartridge plunger position.
A process of manufacturing a medical delivery device, comprising: molding a cartridge to include: a transparent section which acts as a light pipe having an input location; and a light diffusing section optically coupled to the light pipe; and filling the cartridge with a fluid material.
The process according to example 30, further comprising: providing a housing defining a void therein for a cartridge and having a window overlapping with at least part of the void; positioning the cartridge within the void such that the light diffusing section is aligned with the window; positioning at least one light source within the housing and optically coupling the at least one light source to the light pipe through the input location, such that at least some light from the light source entering at the light pipe input is diffused at the light diffusing section and exits the housing through the window.
The device according to example 1, further comprising a housing defining a void therein for the cartridge and having a window overlapping with at least part of the void; wherein the cartridge is positioned within the void, and the light source is positioned within the housing, such that the light diffused at the light diffusing section exits the housing through the window.
The device according to example 1, further comprising a control circuitry having instructions to operate the light source in accordance with a status of the medical delivery device.
The device according to example 1, wherein the light diffusing section comprises a surface area having increased surface roughness sized to distribute the light over an area at least twice an area defined by a surface area of the light source.
The device according to example 1, wherein the cartridge further comprises indicia, and wherein the light diffusing section is positioned in proximity to the indicia, such that the light pipe and the indicia are viewable from a single viewing direction (possible for two windows or more).
The method according to example 19, wherein the state of the medical delivery device comprises at least one of an ongoing delivery state, a stop delivery state, an on or off state, device malfunction state and any combination thereof.
The method according to example 19, wherein the operating the at least one light source comprises turning the light source in a continuous manner or in an intermittent manner.
The process according to example 30, further comprising operatively coupling the at least one light source with a control circuitry and programming the control circuitry to operate the at least one light source according to a state of the device.
The process according to example 30, further comprising programming the control circuitry to adjust a light generated by the at least one light source according to an inventory status of the fluid material.
The process according to example 30, further comprising molding the light diffusing section in a position allowing view of a physical indicator of an inventory state of the fluid material.
A medical delivery device having a void for containing a cartridge and at least one window, comprising:
The device according to example 50, wherein at least a portion of the layer comprises an adhesive surface for attaching onto a surface of the cartridge.
The device according to example 50, wherein the layer is at least partially transparent.
The device according to example 52, wherein the light diffusing section comprises at least one marking, the marking diffuses a limited range of wavelengths.
The method according to Example 53, wherein the marking is text directed to a user indication of the device.
The device according to Example 50, wherein the layer is configured to diffuse light having a wavelength selected according to at least one visual perceptive property of said fluid.
A pharmaceutical delivery device comprising: a cartridge containing a fluid, the cartridge including: a light pipe section which acts as a light pipe having an input location; and a light diffusing section optically coupled to the light pipe; and a light source optically coupled to the cartridge at the input location to the light pipe, such that at least some light from the light source entering at the input location is diffused at the light diffusing section.
The device according to Example 1, further comprising a housing defining a void therein for the cartridge and having at least one window, at least one of which overlapping with at least part of the void; wherein the cartridge is positioned within the void and the light source is positioned within the housing, such that the at least some light which is diffused at the light diffusing section, exits the housing through the window.
The device according to any of Examples 1, 19, 30, 50, 56 and 57, wherein the fluid is a bioactive material.
The device according to any of Examples 56-58, further comprising a control circuitry having instructions to operate the light source in accordance with a status of the pharmaceutical delivery device.
The device according to any of Examples 56-59, wherein the light diffusing section comprises at least one protruding element.
The device according to Example 60, wherein the protruding element at least partially surrounds a circumference of the cartridge.
The device according to Example 60, wherein the protruding element extends at an angle beyond a tangent to a wall of the cartridge.
The device according to any of Examples 56-62, wherein the light diffusing section comprises a surface area having increased surface roughness sized to distribute the light over an area at least twice an area defined by a surface area of the light source.
The device according to any of Examples 56-63, wherein the cartridge further comprises indicia, and wherein the light diffusing section is positioned in proximity to the indicia, such that the light pipe and the indicia are viewable from a single viewing direction.
The device according to any of Examples 56-64, wherein the light source is provided at a number having a range of 2 to 7 light sources.
The device according to any of examples 56-65, wherein the light diffusing section is the cartridge wall.
The device according to any of Examples 56-11, wherein the light diffusing section transmits 80% of the light from the light source.
The device according to any of Examples 56-57, wherein the light diffusing section is a plunger provided in the cartridge.
A method for indicating a user about a state of a pharmaceutical delivery device comprising: optically coupling at least one light source with a cartridge containing a fluid and having a light input location; optically coupling through the cartridge a light diffusing section to the light input location; positioning the at least one light source and the cartridge in a housing having at least one window, such that the light diffusing section is aligned with the at least one window; and operating the at least one light source in accordance with a state of the pharmaceutical delivery device.
The method according to Example 69, wherein the state of the pharmaceutical delivery device comprises at least one of an ongoing delivery state, a stop delivery state, an on or off state, device malfunction state and any combination thereof.
The method according to Example 69, wherein the state of the pharmaceutical delivery device comprises an inventory status of the fluid.
The method according to any of Examples 69-71, wherein the operating the at least one light source comprises turning the light source in a continuous manner or in an intermittent manner.
The method according to any of Examples 69-72, wherein the operating the at least one light source comprises changing the light source color.
A process of manufacturing a pharmaceutical delivery device, comprising: forming a cartridge to include: a transparent section which acts as a light pipe having an input location; and a light diffusing section optically coupled to the light pipe; and filling the cartridge with a fluid.
The process according to Example 19, further comprising: providing a housing defining a void therein for a cartridge and having a window overlapping with at least part of the void; positioning the cartridge within the void such that the light diffusing section is aligned with the window; positioning at least one light source within the housing and optically coupling the at least one light source to the light pipe through the input location, such that at least some light from the light source entering at the light pipe input is diffused at the light diffusing section and exits the housing through the window.
The process according to Example 74, wherein the forming comprises molding.
The process according to Example 76, wherein the molding comprises using Crystal Zenith.
The process according to any of Examples 74-77, further comprising operatively coupling the at least one light source with a control circuitry and programming the control circuitry to operate the at least one light source according to a state of the device.
The process according to Example 78, further comprising programming the control circuitry to adjust a light generated by the at least one light source according to an inventory status of the fluid.
The process according to any of Examples 74-79, further comprising forming the light diffusing section in a position allowing view of a physical indicator of an inventory state of the fluid.
A pharmaceutical delivery device having a void for containing a cartridge and at least one window, comprising: a cartridge containing a fluid, wherein at least part of the cartridge is lined with a layer, the layer acts as a light pipe having a light input location, and the layer further comprises a light diffusing section optically coupled to the light pipe and aligned with the window when the cartridge is positioned in the void; and a light source optically coupled to the layer at the input location to the light pipe, such that at least some light from the light source entering at the input location is diffused at the light diffusing section.
The device according to Example 81, wherein at least a portion of the layer comprises an adhesive surface for attaching onto a surface of the cartridge.
The device according to any of Examples 81-82, wherein the layer is at least partially transparent.
The device according to Example 83, wherein the light diffusing section comprises at least one marking, the marking diffuses a limited range of wavelengths. Example 85: The method according to Example 84, wherein the marking is text directed to a user indication of the device.
The device according to any of Examples 81-85, wherein the layer is configured to diffuse light having a wavelength selected according to at least one visual perceptive property of the fluid.
A cartridge for positioning within a pharmaceutical delivery device having a housing, the cartridge comprising: a light pipe section which acts as a light pipe having an input location; and a light diffusing section optically coupled to the light pipe; wherein the light diffusing section extends beyond a plane defined by the housing.
The cartridge according to Example 87, wherein when the input location is optically coupled to a light source, at least some light from the light source entering at the input location is diffused at the light diffusing section.
The cartridge according to any of Examples 87-88, wherein the cartridge and the light diffusing section are made from the same material.
Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.
Implementation of the method and/or system of embodiments of the invention can involve performing or completing selected tasks manually, automatically, or a combination thereof. Moreover, according to actual instrumentation and equipment of embodiments of the method and/or system of the invention, several selected tasks could be implemented by hardware, by software or by firmware or by a combination thereof using an operating system.
For example, hardware for performing selected tasks according to embodiments of the invention could be implemented as a chip or a circuit. As software, selected tasks according to embodiments of the invention could be implemented as a plurality of software instructions being executed by a computer using any suitable operating system. In an exemplary embodiment of the invention, one or more tasks according to exemplary embodiments of method and/or system as described herein are performed by a data processor, such as a computing platform for executing a plurality of instructions. Optionally, the data processor includes a volatile memory for storing instructions and/or data and/or a non-volatile storage, for example, a magnetic hard-disk and/or removable media, for storing instructions and/or data. Optionally, a network connection is provided as well. A display and/or a user input device such as a keyboard or mouse are optionally provided as well.
Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.
In the drawings:
The present invention, in some embodiments thereof, relates to a visual user indicator and, more particularly, but not exclusively, to a medicament delivery device used as a user indicator light.
Overview
An aspect of several embodiments of the invention relates to using a cartridge as a light pipe for indicating a status of a pharmaceutical delivery device. In some embodiments, a light pipe refers to light traveling and/or diffusing and/or being transmitted and/or guided in at least a portion of a volume of a cartridge wall, the cartridge optionally containing a medicament, e.g. a bioactive material. For example, a bioactive material is any composition having a therapeutic effect on a patient's body. Alternatively, a medicament is a non-bioactive material, such as for example, placebo. In some embodiments, the cartridge comprises a light diffusing section, e.g. an element being optically coupled to the light pipe and serving to diffuse light out of the cartridge wall. Alternatively or additionally, a light diffusing section acts as a light input, collecting light form a light source and into the cartridge pipe light. Optionally, such a cartridge is being used as a user indicator module in a drug delivery device, such as for example an injector device.
As used herein, a cartridge is a compartment containing fluid, and having a needle. In some embodiments, the needle is parallel with respect to the longitudinal axis of the cartridge. Alternatively, the needle is bent with respect to the longitudinal axis of the cartridge, optionally being substantially perpendicular to it. Fluid, as used herein, refers to a liquid and/or gas used for medical purposes. In some embodiments, fluid includes a medicament, optionally a bioactive material such as a drug, or a non-bioactive material such as a placebo. In some embodiments, fluid includes a suspension, and/or a solution, and/or a mixture of miscible or immiscible liquids.
In some embodiments, a light source is optically coupled to the cartridge, wherein at least some of the light generated by the light source is transmitted and/or guided and/or diffuses and/or travels across at least a portion of the volume of the cartridge wall. In some embodiments, a light source is optically coupled to the cartridge by a light diffusing section positioned on the cartridge such that it is embedded within the injector device; optionally the light diffusing section is not viewable from outside a housing containing the cartridge and only serves as a light input location. Alternatively or additionally, a light diffusing section optically coupled to light traveling in the cartridge, is positioned on the cartridge in a position which is viewable from outside a housing containing the cartridge.
For example, light generated by the light source travels to a light diffusing section embedded in the injector device and serving as a light input, and the light input guides the light to travel through at least a portion of the volume of the cartridge. Optionally, a second light diffusing section, optionally positioned substantially opposite to the light input, guides the light traveling through the volume of the cartridge to be viewable from the opposite direction of the cartridge. Alternatively or additionally, light diffuses through the fluid contained in the cartridge.
In some embodiments, at least two windows are provided in an injector housing, optionally for allowing a user to view more than one portion of the cartridge. Optionally, at least one window allows viewing of the medicament and/or plunger. Alternatively or additionally, at least one window allows viewing of the light diffusing section. In some embodiments, the same window allows viewing of both the medicament (and/or plunger) and the light diffusing section. A potential advantage of having a window to view the medicament, through which light is also transmitted, is that light generated within the injector assists in improving the inspection of the medicament status in the injector.
In some embodiments, light is generated by the light source in accordance with a state of a delivery cartridge device. In some embodiments, state is an operation status of the device, for example an ongoing delivery state and/or a stop-delivery state and/or an end-of-delivery state and/or an on/off state of a motor and/or availability of an electricity source and/or device malfunction. Alternatively or additionally, state is an inventory status of the amount of fluid delivered and/or left in the cartridge.
A potential advantage of using a medicament cartridge to transmit a user indicator light is reducing the need to add a separate module of an indicator light to a delivery device. Reducing the number of modules in a device is likely to reduce possible malfunctions of the device. In addition, another potential advantage is an enlarged surface area exhibiting the indicator light, which is likely to be viewable from a wide range of viewing angles. Usually the delivery cartridge surface visible by a user is larger than the typical indicator light provided in a separate module, and therefore, a user may detect the indicator light with greater ease and by looking from many different angles. In some embodiments, most of the light generated within the device comes out of the cartridge, e.g. at least 90%, or at least 80% or at least 70%, or at least 60%.
In some embodiments, a light source positioned in proximity to a cartridge containing a medicament serves a double role: a first role comprises being a status indicator light configured to travel through at least a portion of the cartridge wall and be in a viewing path of a user. A second role comprises lighting the cartridge content, enabling viewing of the medicament status in the cartridge, and/or viewing of indicia provided on the cartridge wall and/or viewing of a plunger position. In some embodiments, using the same window, a user can see an indication light of the status of the device operation simultaneously with observing the status of the medicament, such as for example the fluid level of the medicament, and/or the plunger position, and/or indicia markings. A potential advantage of having the same observation window for the above indication is that it gives a user a redundant view of two indicators possibly reducing the probability of misinterpretation and/or providing to the user an indicator of when there is a malfunction in one of the indicators. In some embodiments, at least two windows are provided, at least one for viewing at least the medicament and at least one for viewing at least a cartridge light guide. Optionally, both windows are positioned to enable viewing at the same time.
In some embodiments, the same light source illuminates the cartridge (potentially facilitating reading of the graduation and/or the level of medicine) and/or includes a coded status indicator (e.g. color and/or flickering). In some embodiments, light properties are suitable to a light traveling characteristic of the medicament, e.g. different light features are used if the medicament is opaque, or transparent or translucent. In some embodiments, the color of the light source is determined in accordance with a medicament color. In some embodiments, the medicament can be a material having any color. Alternatively or additionally, the medicament can have a milky and/or opaque appearance.
In some embodiments, a plunger configured for facilitating the medicament, provides a change in the total reflection of the light traveling through the cartridge wall, optionally causing light to diffuse out of the cartridge wall to a direction of a user, at the point where the plunger edge contacts the cartridge wall, providing a light indication of the plunger position. Alternatively or additionally an optical element (for example a diffuser and/or a reflector) may be added to the plunger, for example at the base (e.g. the proximal end) of the plunger. Alternatively or additionally, a wall of the plunger being in contact with the cartridge can serve as a light guide.
In some embodiments, a housing is provided having an observation window enabling a user to view a delivery cartridge serving as a light pipe embedded in the housing. Optionally, an observation window is any aperture in a housing containing a delivery cartridge and enabling a user a visual view of the cartridge. In some embodiments, the observation window is provided for a user visual detection of an indicator light embedded inside the housing and having a light path to the cartridge. Optionally, the observation window serves as a visual indicator of a light produced inside the housing traveling across a volume of the cartridge. Potentially the observation window is doubly used for the detection of an indicator light and for a user visual inspection of the cartridge content. Alternatively or additionally, the cartridge is provided with an appendage having light transmitting and/or diffusing properties. Optionally an observation window may include a pane and/or may include an open space.
In some embodiments, operation status is indicated by using a plurality of light wave properties, for example, frequency and/or amplitude and/or duration. In some embodiments, light is transmitted continuously. Alternatively or additionally, light is transmitted intermittently, for example by flickering. In some embodiments, light properties include frequency of flickering, which might increase or decrease over time. For example, flickering frequency, in some embodiments, is correlated to the delivery speed and/or is correlated with a medicament amount having been delivered.
In some embodiments, the cartridge serves as a pipe light by having at least a portion of a transparent section. As used herein, transparent relates to a material allowing at least some traveling of light therethrough. In some embodiments the cartridge comprises a light diffusing section in the form of an appended visual feature. In some embodiments, the visual feature is configured to guide (i.e. transmit) a light path through it. Alternatively or additionally, the visual feature is configured to diffuse light through it. In some embodiments, the visual feature protrudes from the surface of the cartridge, optionally made of the same material as the cartridge, optionally molded with the outer surface of the cartridge. Alternatively, the visual feature is in a different composition than the cartridge and is designed to guide and/or diffuse light around at least a partial circumference of the cartridge.
In some embodiments the visual feature comprises a plurality of protrusions, for example circumferential protruding ribs and/or segments of circumferential protruding ribs, optionally orthogonal to the longitudinal axis of the cartridge. Alternatively or additionally, the visual feature comprises a plurality of spaced apart bulges. A potential advantage of a surface having protrusions thereon is that protruding elements are likely to transmit and/or diffuse a greater amount of light with respect to a smooth surface. In some embodiments the protrusions are equidistant, probably enabling substantial uniform transmission of light. Alternatively, the protrusions are asymmetrically distributed, probably enabling more light to transmit to a predefined surface region.
Alternatively or additionally, the visual feature comprises a plurality of slots and/or grooves. Alternatively or additionally, the visual feature comprises at least one protrusion and at least one slot. Potentially, either protrusions and/or slots are configured to make light traveling through the volume of the cartridge's wall to diffuse outside of the cartridge wall. Alternatively or additionally, at least a portion of the cartridge wall comprises increased roughness, causing light to diffuse out of the cartridge wall. In some embodiments, surface textures such as bulges and/or slots and/or roughness are provided on the outer surface of the cartridge wall. Alternatively or additionally, surface textures are provided on the inner surface of the cartridge wall.
In some embodiments, protrusions are arranged in a group, guiding a light path from an individually operated light source. Optionally, a plurality of such groups is provided, each being coupled to a distinctly operated light source. A potential advantage of multiple individually operated groups is the increase of visual information provided to the user simultaneously, by having a different interpretation assigned to each group of protrusions. For example, a first group of protrusions is linked to a first light source indicating, e.g., the delivery operation state of the device, and a second group of protrusions is linked to a second light source indicating e.g., the state of the medicament amount.
In some embodiments the visual feature comprises a projecting element having light guiding and/or diffusing properties. In some embodiments, the element is projected beyond a plane defined by the cartridge and/or the housing. A potential advantage of a light transmitting projecting element is its likelihood to better guide a propagation of light through it. In addition, a protruding element is likely to be seen and/or noticed more conveniently from a variety of observation angles.
In some embodiments, a projecting element includes a light diffusing section configured to extend beyond a plane defined by the housing of cartridge and/or a plane defined by the inner edge of a window and/or a plane defined by an outer edge of a window. A potential advantage of extending beyond the housing and/or the edge of the window is an increase in a user available viewing angles of the light diffusing section. In some embodiments, more than one light diffusing section is provided, optionally each being coupled to a different light source.
In some embodiments the cartridge comprises at least one alignment guide defining an orientation of the cartridge with respect to an embedding injector device. In some embodiments, the alignment guide projects beyond the outer surface of the cartridge. Alternatively, the alignment guide comprises a recess in the outer surface of the cartridge. Optionally, the alignment guide interlocks with a complementary geometrical feature within the injector device, optionally preventing rotation of the cartridge with respect to the device. Potentially, alignment guides enable positioning of the cartridge at a predefined orientation, for example with respect to the observation window of the device housing and/or a light source, optionally allowing an appended visual feature to be visible to a user.
An aspect of several embodiments of the invention relates to a process of manufacturing a light transmitting and/or diffusing cartridge for medicament delivery to serve as a user indicator module, used for example in an injector device.
In some embodiments, a drug delivery device is provided by embedding a cartridge in a housing having a window at least partially aligned with the cartridge position. Optionally, the window follows a cartridge's longitudinal axis, or any axis across which a medicament is expelled.
In some embodiments, at least one light source is positioned within said housing such that it is optically coupled to the cartridge. In some embodiments a range of 1 to 10 light sources is provided. Alternatively a range of 2 to 7 light sources is provided. Alternatively, a range of 3 to 6 light sources are provided. Alternatively 4 light sources are provided.
In some embodiments a cartridge is manufactured from a material which permits traveling of electromagnetic waves in a visible frequency range. Optionally, the material is at least partially transparent, optionally providing view of the composition being delivered. Alternatively, the cartridge is internally coated with an opaque material, such as for example in the case of a light-sensitive medicament, but the cartridge wall enables visible light to diffuse across its volume. In some embodiments, at least part of the cartridge is manufactured using Crystal Zenith, optionally by molding. Alternatively or additionally, at least part of the cartridge is manufactured using glass. Alternatively or additionally, at least part of the cartridge is manufactured using a standard material known in the art to be used for cartridges.
In some embodiments the cartridge is molded asymmetrically, optionally having transmitting/diffusing elements where an observation window is designed to be fit with respect to the cartridge. Alternatively or additionally, the cartridge is molded having transmitting/diffusing elements which are embedded inside the injector housing, optionally not viewable from the outside. Alternatively or additionally, the cartridge is molded to have a defined angle with respect to the observation window and housing plane.
In some embodiments, the cartridge is manufactured from layers having at least two materials. Optionally, at least one of the layering materials is opaque. Alternatively or additionally, at least one of the layering materials is transparent, optionally partially. In some embodiments, in at least one of the layers visible light travels and/or diffuses throughout its volume.
An aspect of some embodiments of the invention relates to a light guiding liner and/or sticker sized and shaped to line at least a portion of a medicament cartridge. In some embodiments, the sticker comprises a material having light diffusing properties, i.e. light can travel and/or diffuse and/or be transmitted through at least a portion of the volume of the sticker. Optionally, at least a portion of the sticker surface comprises an adhesive material for adhering onto a cartridge inner and/or outer surface. In some embodiments, the sticker includes text and/or markings over it surface, optionally visible only when being exposed to light being in a particular wavelength range.
Optionally, the sticker is visible only when sharing a visual path with a light having a wavelength in the range of 400-450, and/or 450-480, and/or 480-490 and/or 490-500, and/or 500-560, and/or 560-580, and/or 580-600, and/or 600-650 and/or 650-750, and/or any range larger, smaller or intermediate range.
In some embodiments, the text and/or markings comprise a light diffusing material and are lit once light travels to them from a light input location. Optionally, the sticker comprises a light input located inside an injector housing, and sharing a visual path with at least one light source embedded within the housing. Alternatively or additionally, text and/or markings are visible by having only a contour which is a light guiding material. Alternatively or additionally, the text and/or markings are visible by being surrounded by a light guiding sticker and not guiding light themselves, such as by punching the text and/or markings out of the sticker and creating a material-free space being in the shape of the text and/or markings.
In some embodiments, the cartridge and/or syringe is manufactured in a process distinct from the filling of the fluid reservoir. Accordingly, optionally, some light guide types are provided in the first process and other light guide types are provided in the second process. For example, molded light guide features may be provided through the molding process of the cartridge, while the liner may be assembled onto the cartridge by a different manufacturer, either before or after filling and/or sealing with the plunger. In some embodiments, the light guide features provided by the first process are configured to be compatible to a variety of light sources and/or fluids. Alternatively or additionally, the light guide features provided by the second process are specifically tailored to the specific fluid type and/or light properties of the fluid being used for filling. Optionally, the features in the first process are provided independently from the features in the second process.
Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details of construction and the arrangement of the components and/or methods set forth in the following description and/or illustrated in the drawings and/or the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.
Exemplary User Indicator Light Path for Use in a Drug Delivery Device
Referring now to the drawings,
In some embodiments, cartridge 102 is configured to serve as a light pipe, bridging light generated by light source 104 to window 162. Optionally, cartridge 102 comprises a light input location 122 sharing an optical pathway with the light source 104. In some embodiments, cartridge 102 is made of a material having light propagating properties. Optionally at least a portion of the wall of cartridge 102, serves as a light pipe 124 for transmitting light at least through a portion of its volume.
In some embodiments, cartridge 102 comprises a light diffusing section 126. Optionally, light diffusing section 126 comprises an extending element. Optionally, the extending element is substantially perpendicular to a longitudinal axis of cartridge 102, as shown for example in
In some embodiments, light diffusing section 126 comprises an arrangement along a longitudinal axis of the cartridge. Alternatively or additionally, light diffusing section 126 comprises an arrangement along at least a portion of the cartridge circumference. In some embodiments, light pipe 124 comprises a material extending along at least a portion of the cartridge 102 circumference, serving as a light pipe between a light source positioned in proximity to one portion of the light pipe, to a light diffusing section positioned in proximity to a second portion of the light pipe.
In some embodiments, light generated by light source 104 travels through light path 110. Optionally, light generated by light source 104 travels to light input 122 found in cartridge 102. In some embodiments, light travels from light input 122 into the light pipe 124 of cartridge 102. Optionally, light pipe 124 includes a transparent section of cartridge 102. In some embodiments, light pipe 124 comprises the entire volume of the wall of cartridge 102. Alternatively, only a portion of cartridge 102 is made of a material enabling light traveling. In some embodiments, cartridge 102 comprises layers of materials, at least one of which allows light to travel through it.
In some embodiments, light traveling through light path 110 is internally reflected except for when encountering light diffusing section 126. In some embodiments, light diffusing section 126 is shaped to allow light traveling through light path 110 to diffuse out of the internal volume of cartridge 102.
In some embodiments, window 162 is aligned with cartridge 102 such that light diffusing section 126 is viewable through window 162. As such, in some embodiments, light traveling through light path 110 diffuses out of light diffusing section 126 and out 112 of housing 106.
In some embodiments, window 162 is positioned in a top cover of housing 106, optionally near the position of an operation button. Alternatively or additionally, window 162 is positioned in a base of housing 162, optionally near a position of a removable safety liner.
In some embodiments, window 162 is shaped as a circle. Alternatively or additionally, window 162 is shaped as an ellipse or an elongated polygon, optionally aligned with a longitudinal axis of cartridge 102. Alternatively or additionally, window 162 is shaped as a slot.
In some embodiments, housing 106 comprises a plurality of windows 162, optionally aligned with different segments of cartridge 102. Alternatively or additionally, window 162 includes a viewing section in-between a plurality of housing compartments. For example, if housing 106 is provided in a multi-part configuration, the plurality of housing parts are optionally assembled such that at least a portion of cartridge 102 can be viewed in between the housing parts. Optionally, cartridge 102 serves as a connector between pluralities of housing parts, for example, by having at least one housing for a proximal end of the cartridge and a separate at least one housing for the distal end of the cartridge, while at least a portion of the middle section of the cartridge is available for viewing in between the proximal and distal housing compartments.
Exemplary Drug Delivery Device Having a Cartridge Used as a Light Pipe
Reference is now made to
In some embodiments, light diffusing section 126 is found on the dorsal side of the cartridge, i.e. the side that faces window 162. In such embodiments, light diffusing section 126 is optionally used to transmit light diffusing through the walls of cartridge 102. Alternatively or additionally, light diffusing section is found on the ventral side of the cartridge, i.e. the side that faces the inner portion of injector 201. In such embodiments, light diffusion section 126 optionally serves as a light input, collecting light generated inside injector 201 by light source 104, and transmitting the light to the cartridge walls, a light which is then viewable through window 162. In some embodiments, window 162 comprises a dome, e.g. a curved material and/or cylindrically shaped cover, for covering and/or protecting the cartridge. A potential advantage of providing a curved covering is in protecting light diffusion section 126 if it extends beyond the surface of housing 106. Typically, a protective cover is useful when the cartridge and/or light diffusing section 126 are made of glass and prone to break if receiving a shock. In some embodiments, the dome projects from a plane defined by the surface of the housing by at least 0.5 mm, and/or at least 1 mm, and/or at least 2 mm, and/or at least 5 mm.
In some embodiments, window 162 serves a second role when allowing viewing of plunger 202, which is configured to push a medicament out of cartridge 102 through a fluid outlet, located at location 208. Optionally, plunger 202 is pushed by motor 206. Alternatively or additionally, window 162 allows viewing of the medicament fluid level found in cartridge 102. Alternatively, cartridge 102 comprises an inner layer which is opaque, for protecting light sensitive medicaments.
In some embodiments, a control circuitry 204 is provided, optionally having instructions to operate light source 104. For example, control circuitry 204 in some embodiments can get input from motor 206 as to an operation state of the device, and optionally accordingly provide instructions for light generation by light source 104. Alternatively or additionally, control circuitry 204 in some embodiments can get input as to a plunger 202 position, and optionally accordingly provide instructions for light generation by light source 104.
Optionally, housing 106 comprises at least two windows 162 and 164. In some embodiments, window 164 allows viewing of the distal portion 302 of cartridge 102. Optionally, the distal portion of cartridge 102 comprises a light diffusing section in the form of a flange 210, which is further illustrated in detail in
Exemplary Drug Delivery Device Housing and Cartridge
Reference is now made to
In some embodiments, a drug delivery device, such as for example an injector, comprises a housing 106 having a window 162. In some embodiments, housing 106 comprises a void 164 sized and shaped to accommodate a cartridge 102. Optionally, window 162 is provided in accordance with the void 164 such that the cartridge 102 is at least partially viewable from the window. In some embodiments, the portion of the cartridge viewable from the window is configured to serve as a user indicator light, optionally by including in the viewable portion a light diffusing section 126.
In some embodiments, cartridge 102 comprises a proximal end 304 defined by having a needle accommodating member 208, and a distal end 302 defined by having a bore 310 for accommodating a plunger. In some embodiments, plunger is configured to be pushed along a longitudinal axis of cartridge 102, optionally, being aligned with the longitudinal axis of window 164. In some embodiments, non-symmetric orientation features of the cartridge lead to positioning of the cartridge such that the distal end 302, proximal end 304 and the light diffusing section 126 are correctly aligned with housing 106 and/or window 162. For example, interlocking members could be provided in cartridge 102 and housing 106. In some embodiments, such non-symmetric orientation alignment features keep cartridge 102 from shifting and/or rotating within housing 106. Alternatively or additionally, a distal and/or proximal end of the cartridge includes a connector, such as for example a septum and/or a physical connecting feature, e.g. a snap and/or a circumferential lip.
In some embodiments, light source 104 is positioned in housing 106 such that it shares an optical pathway with at least a portion of cartridge 102, optionally with a portion comprising a transparent section for allowing light to travel through a volume of cartridge 102, optionally through its wall. In some embodiments, more than one light source is provided, optionally more than 2. Alternatively, more than 3 light sources are provided. Alternatively more than 4 light sources are provided. In some embodiments, each light source is optically coupled to a different light pipe provided in cartridge 102, and/or optically coupled to a different light diffusing section. In some embodiments, a plurality of light sources is provided to enhance the viewing area of the indication light, optionally having all light sources operated in the same manner. Alternatively, a plurality of light sources is provided to allow different indications operated simultaneously, for example, a green light indicates operating status of the device motor and it is simultaneously turned on together with a blinking red light indicating delivery. In some embodiments, light source 104 comprises a light emitting diode.
Exemplary Cartridge Having an Extended Light Diffusing Section
Reference is now made to
In some embodiments, light diffusing surface 462 is provided to diffuse light traveling in light pipe 402, optionally being a wall of cartridge 102. In some embodiments, light pipe 402 comprises the entire wall of cartridge 102 extending from distal portion 302 to proximal portion 304. Alternatively, light pipe 402 is provided by having a transparent section only in a portion of cartridge 102, optionally, only a portion of a longitudinal axis. Alternatively, light pipe 402 is provided by having a transparent section only in a portion of cartridge 102, optionally, only a portion of a circumference of the cartridge 102.
In some embodiments, light diffusing section 462 extends at an angle beyond a plane being tangent to the circumference of cartridge 102. Alternatively or additionally, light diffusing section 462 extends to a direction perpendicular to the longitudinal axis of cartridge 102. In some embodiments, light diffusing section 462 comprises a longitudinal axis substantially aligned with the longitudinal axis of cartridge 102. Alternatively, light diffusing section 462 comprises a longitudinal axis substantially perpendicular to the longitudinal axis of cartridge 102.
In some embodiments, section 462 is molded with the cartridge in a molding process. Alternatively or additionally, section 462 is added to the cartridge, optionally by providing section 462 to be sized and shaped to fit at least a portion of the cartridge. In some embodiments, section 462 is pressed against the light transmitting wall/layer of the cartridge.
Optionally, the distal end 302 of cartridge 102 comprises a flange 210. In some embodiments, flange 210 serves as a light diffusing section, in addition to or instead of light diffusing section 462. In some embodiments, flange 210 comprises an edge at least partially surrounding the perimeter of distal end 302, optionally having at least one brim feature 317 extending beyond the perimeter of distal end 302 in a direction away from the central axis of cartridge 102. Potentially, brim feature 317 can guide light generated by light source comprised in the housing, and optionally deliver the light through flange 210. In some embodiments, at least a portion of flange 210 delivering the light is viewable from outside the housing. Alternatively or additionally, flange 210 and/or brim 317 are sized and shaped to complement at least one feature comprised in the housing, potentially fixing an orientation of the position of the cartridge within the housing.
A potential advantage of guiding light through a light diffusing section provided in the distal end 302 of cartridge 102 is that the distal end region is potentially free of medicament, which is probably located in a more proximal position of the cartridge, after the plunger. An environment without medicament potentially allows light to diffuse without interference or altering effects, which might be caused by a presence of a medicament.
Exemplary Cartridge having a Light Diffusing Surface Area
Reference is now made to
In some embodiments, light diffusing surface area 562 is provided in cartridge 102. In some embodiments, surface area 562 is configured to diffuse light traveling through light pipe 502 provided by cartridge 102 by having a rough surface. In some embodiments, a rough surface is defined as a surface which is not tangential to the cartridge circumference and/or extending in a variety of angles, optionally without order. In some embodiments, the greater the angles of the non-tangential surfaces, the greater the roughness level is defined. Potentially, light traveling through light pipe 502 is internally reflected when encountering a smooth surface and/or diffuses out of the light pipe when encountering rough surface 562.
In some embodiments, more than one rough surface area 562 is provided. In some embodiments, surface area 562 is configured to diffuse light in an even manner, i.e. diffuse equal portions of light per area unit. Alternatively, surface area 562 is configured to provide unequal portions of light to diffuse per area unit, for example, by having a gradient of roughness level and/or areas of greater/smaller roughness level.
Reference is now made to
In some embodiments, sticker 564 comprises at least one marking 566, which is optionally text and/or indicia and/or a symbol and/or any other visual mark. Optionally, marking 566 is only visible when a shared-path light is generated within the injector housing. In some embodiments, marking 566 is only visible when the light generated inside has a particular range of wavelengths, for example, being in the range of 400-450, and/or 450-480, and/or 480-490 and/or 490-500, and/or 500-560, and/or 560-580, and/or 580-600, and/or 600-650 and/or 650-750, and/or any range larger, smaller or intermediate range. In some embodiments, an adhesive layer and/or a sticker has a thickness in the range of about 0.05 mm to about 1 mm. Alternatively, a thickness is in a range of 0.25 mm to about 0.75 mm.
Optionally, marking 566 is visible sharing a visual path with an inner light source, while the surrounding sticker 564 does not guide light through it. Alternatively or additionally, marking 566 and surrounding sticker 564 guide light having different wavelength ranges. Alternatively or additionally, only surrounding sticker 564 guides light, while marking 566 does not, such as for example, by punching out the area being taken by and/or the outline surrounding marking 566. In some embodiments, marking 566 is printed on the sticker before its placement onto the cartridge. In some embodiments, marking 566 comprises text, optionally directed to a user indication of the device, such as for example, indicating “OK” and/or “Error” if the device malfunctions, and/or “Cold”. User indicating text is optionally provided to a user using a different color, or a different range of wavelengths, for each user indicating text. For example, “Error” may be indicated with a red light and/or provided with a red filter, “OK” may be presented as green and “Cold” may be presented with blue.
In some embodiments, sticker 564 is flexible. Optionally, sticker 564 can be lined over any commercially available cartridge. In some embodiments, sticker 564 is lined over at least a portion of a cartridge which has been manufactured by molding, after the molding process is done, optionally before cartridge 502 is filled with a medicament. Alternatively, sticker 564 is lined over cartridge 502 after the cartridge is filled. In some embodiments, at least part of sticker 564 is transparent. Alternatively or additionally, at least part of sticker 564 is semi-transparent. Alternatively or additionally, at least part of sticker 564 is opaque.
In some embodiments, sticker 564 is configured to transmit light having a particular range of wavelengths. The wavelength transmitted by sticker 564 is optionally selected according to at least one visual perceptive property of the medicament comprised in the cartridge. In some embodiments, a visual perceptive property comprises the color of the medicament. Alternatively or additionally, the visual perceptive property includes the reflectivity of the medicament. Alternatively or additionally, the visual perceptive property includes the absorbance of the medicament.
Exemplary Cartridge Having Light Diffusing Protruding Elements
Reference is now made to
In some embodiments, at least one protruding element 662 is provided, extending along at least a portion of a circumference of cartridge 102. In some embodiments, a plurality of protruding elements 662 is provided. Optionally, the protruding elements 662 are arranged equidistantly, optionally along a longitudinal axis of cartridge 102. A potential advantage of equidistant elements 662 is a uniform view from a variety of viewing angles. Alternatively, protruding elements 662 are arranged non-equidistantly, optionally with respect to a longitudinal axis of cartridge 102. A potential advantage of non-equidistant elements 662 is for example allowing viewing the medicament being delivered at a portion having elements 662 being more distant from each other.
Exemplary Cartridge Having a Light Diffusing Bulge
Reference is now made to
In some embodiments, light diffusing section of cartridge 102 comprises at least one bulge 762. In some embodiments, bulge 762 comprises a protruding surface limited to a relatively small surface area. In some embodiments, a bulge 762 protrudes from a section area being in a range of about 1% to about 5% of the entire surface area of the cartridge 102. Alternatively or additionally, a bulge 762 protrudes from a section area being in a range of about 10% to about 20% of the entire surface area of the cartridge 102. Alternatively or additionally, a bulge 762 protrudes from a section area being in a range of about 20% to about 30% of the entire surface area of the cartridge 102.
In some embodiments, a bulge 762 extends to a height being no more than 0.2 mm. Alternatively or additionally, bulges 762 extend to a height being no more than 0.5 mm. Alternatively or additionally, bulges 762 extend to a height being no more than 1 mm.
Exemplary Cartridge Having a Light Diffusing Slot
Reference is now made to
In some embodiments, light diffusing section comprises at least one slot 862 in cartridge 102. In some embodiments, slots 862 are provided as etched elements in cartridge 102. Optionally, slots 862 are provided along an entire circumference of cartridge 102. Alternatively or additionally, slots 862 are provided along a portion of the circumference of cartridge 102. Alternatively or additionally, slots 862 are provided being parallel to a longitudinal axis of the cartridge 102. Optionally, longitudinally aligned slots 862 enhance the optical path of viewing the fluid inventory status of the medicament. Optionally the inner surface of a slot may be smooth and/or rough and/or having a varying roughness.
Exemplary Cartridge Having a Light Diffusing Plunger Contact
Reference is now made to
In some embodiments, plunger 202 defines a contact wall 962 with an inner wall of cartridge 102. In some embodiments, contact wall 962 serves as a light diffusing section by causing light to diffuse at the contact wall with plunger 202. In some embodiments, light emitted by contact wall 962 helps to identify the location of the plunger, potentially aiding in following a delivery of a medicament. In some embodiments, the light diffusing wall is at the proximal portion of the plunger (where the plunger contacts the medicament). Locating the light diffusing section at the proximal end of the plunger has the potential advantage of showing the contact point of the medicament with the plunger. Alternatively or additionally the light diffusing wall is at the distal end of the plunger. Alternatively or additionally, the light diffusing wall is located between the distal and proximal ends of the plunger. In some embodiments, indicia are provided for gauging the volume of medicament remained based on the location of the light diffusing wall of the plunger.
Exemplary Manufacturing Process
Reference is now made to
In some embodiments, a process begins by molding a cartridge 1002 configured for serving as a light pipe and having a light diffusing section. Optionally, the entire cartridge is molded using a transparent material, optionally a polymer, optionally, Crystal Zenith and/or glass. Alternatively or additionally, only a portion of a cartridge is molded using transparent material, optionally the portion defines a light input location. Optionally, the molded cartridge is coated internally with a second material layer, optionally having different light propagating characteristics than the molding material.
In some embodiments, after molding the cartridge, lining of the cartridge surface is provided 1003, for example, by lining at least a portion of the cartridge surface with a sticker, optionally a sticker which serves as a light diffuser, optionally lining the inner surface of the cartridge. Alternatively or additionally, the sticker lines the outside surface of the cartridge. In some embodiments, the sticker prevents at least a portion of the light from reaching the medicament, potentially useful when the medicament used is light-sensitive. In some embodiments, the sticker comprises a reflecting material. Alternatively or additionally, the sticker is provided with written text. Alternatively or additionally, the cartridge is provided with a layer of a light guiding element, optionally by linking in a chemical fashion.
In some embodiments, a sticker which is lined over at least a portion of the cartridge contains light-sensitive illustrations and/or text. Alternatively or additionally, the sticker contains fluorescent features which are detectable only when exposed to a specific range of wavelengths. For example, the sticker contains text and/or indicia which can only be seen when the embedded light source is on and/or when a specific wavelength is emitted. Optionally, the sticker is transparent, or semi-transparent, or opaque.
In some embodiments, once molded, a cartridge is filled with a medicament 1004. Optionally, the light input location and/or the transparent light pipe, and/or the light diffusing section are manufactured according to properties of the medicament being filled. For example, if the medicament is transparent, optionally having a non-transparent portion of the cartridge to avoid light traveling in uncontrolled set ups. Alternatively, when the medicament is light-sensitive, the cartridge is optionally coated with an opaque material.
In some embodiments, a housing having a window is provided 1006. In some embodiments, the cartridge is positioned in the housing 1008 such that the light diffusing section is aligned with the window. Optionally, the housing comprises a void sized and shaped to fit the cartridge. In some embodiments, the housing further comprises members sized and shaped to interlock with portions of the molded cartridge, such that a predefined orientation of the cartridge with respect to the housing is provided. In some embodiments, positioning of the cartridge is conducted such that at least a portion of the cartridge is viewed from the window. Optionally, the portion of the cartridge viewed from the window comprises the light diffusing section.
In some embodiments, at least one light source is positioned in the housing 1010. In some embodiments, the light source is positioned to have an optical path with at least a portion of the cartridge, optionally being a light input location.
Exemplary Manufacturing Light Indication Algorithm
Reference is now made to
In some embodiments, light source is turned on 1102 once the device is turned on 1120, such as for example when electricity power is sensed by a control circuitry. Optionally, a user can start drug delivering. In some embodiments, while medicament delivery is ongoing 1140, the light flickers at flickering frequency A 1104. In some embodiments, when delivery stops 1160, the light source stops flickering 1106, optionally returning to the initial operating state. Alternatively the light source emits light having a different color.
In some embodiments, once a malfunction is identified 1180, the light flickers at frequency B 1108. In some embodiments, once delivery ends 1100, light flickering is stopped and optionally light changed color 1110. In some embodiments, when the device is turned off and/or removed from the user's body 1111, light is turned off 1112.
In some embodiments, improper use is also notified by light, such as when a user accidently removes a device while the device is delivering the medicament.
Optionally, a non-visual indication is also provided for any of the device state indications. For example, vibrations, optionally generated by the motor, are provided. Alternatively or additionally, sound indication may be provided for any indication of the device state.
Exemplary Method for Providing a User Indicator Light in a Drug Delivery Device
Reference is now made to
In some embodiments, a cartridge containing a medicament is used as a user indicator light by optically coupling a light source with a cartridge configured for serving as a light pipe for light generated by the light source 1202. In some embodiments, the cartridge further comprises at least one light diffusing section, which is optically coupled to the light pipe of the cartridge 1204, such that for example, light generated by the light source travels through the light pipe being the cartridge and diffuses out of the cartridge wall through the light diffusing element.
In some embodiments, the cartridge and the light source are positioned in a housing of a drug delivery device having a window 1206. Optionally, the cartridge and/or light source are aligned with respect to the window 1208, such that light generated by the light source travels through the light diffusing section and out of the window.
In some embodiments, the light is operated according to a state of the drug delivery device 1210, in accordance with device states as provided herein.
As used herein the term “about” refers to ±25%.
The terms “comprises”, “comprising”, “includes”, “including”, “having” and their conjugates mean “including but not limited to”.
The term “consisting of” means “including and limited to”.
The term “consisting essentially of” means that the composition, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.
As used herein, the singular form “a”, “an” and “the” include plural references unless the context clearly dictates otherwise.
Throughout this application, various embodiments of this invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases “ranging/ranges between” a first indicate number and a second indicate number and “ranging/ranges from” a first indicate number “to” a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.
As used herein the term “method” refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.
As used herein, the term “treating” includes abrogating, substantially inhibiting, slowing or reversing the progression of a condition, substantially ameliorating clinical or aesthetical symptoms of a condition or substantially preventing the appearance of clinical or aesthetical symptoms of a condition.
It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.
Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.
All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting.
This application is a section 371 of International Application No. PCT/US16/56258, filed Oct. 10, 2016, which was published Jul. 27, 2017 under International Publication No. WO 2017/127141 A1, which is a continuation of U.S. application Ser. No. 15/204,542, filed Jul. 7, 2016, which claims the benefit of U.S. Provisional Application No. 62/281,536, filed Jan. 21, 2016, and a continuation of U.S. application Ser. No. 15/269,248, filed Sep. 19, 2016, the disclosures of which are incorporated herein by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2016/056258 | 10/10/2016 | WO | 00 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2017/127141 | 7/27/2017 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 232432 | Allison | Sep 1880 | A |
| 1125887 | Schimmel | Jan 1915 | A |
| 1321550 | Platt | Nov 1919 | A |
| 1704921 | Nicoll | Mar 1929 | A |
| 1795530 | Cowan et al. | Mar 1931 | A |
| 1795630 | Wilson | Mar 1931 | A |
| 2453590 | Poux | Nov 1948 | A |
| 2589426 | Ogle | Mar 1952 | A |
| 2677373 | George | May 1954 | A |
| 2702547 | Glass | Feb 1955 | A |
| 2860635 | Wilburn | Nov 1958 | A |
| 3203269 | Perrine | Aug 1965 | A |
| 3212685 | James et al. | Oct 1965 | A |
| 3585439 | Schneeberger | Jun 1971 | A |
| 3623474 | Heilman et al. | Nov 1971 | A |
| 3705582 | Stumpf et al. | Dec 1972 | A |
| 3708945 | Klettke | Jan 1973 | A |
| 3794028 | Mueller et al. | Feb 1974 | A |
| 3834387 | Brown | Sep 1974 | A |
| 3994295 | Wulff | Nov 1976 | A |
| 4085747 | Lee | Apr 1978 | A |
| 4189065 | Herold | Feb 1980 | A |
| 4195636 | Behnke | Apr 1980 | A |
| 4218724 | Kaufman | Aug 1980 | A |
| 4254768 | Ty | Mar 1981 | A |
| 4273122 | Whitney et al. | Jun 1981 | A |
| 4300554 | Hessberg et al. | Nov 1981 | A |
| 4324262 | Hall | Apr 1982 | A |
| 4403987 | Gottinger | Sep 1983 | A |
| 4425120 | Sampson et al. | Jan 1984 | A |
| 4435173 | Siposs et al. | Mar 1984 | A |
| 4465478 | Sabelman et al. | Aug 1984 | A |
| 4502488 | Degironimo et al. | Mar 1985 | A |
| 4504263 | Steuer et al. | Mar 1985 | A |
| 4549554 | Markham | Oct 1985 | A |
| 4564054 | Gustavsson | Jan 1986 | A |
| 4565543 | Bekkering et al. | Jan 1986 | A |
| 4583974 | Kokernak | Apr 1986 | A |
| 4585439 | Michel | Apr 1986 | A |
| 4599082 | Grimard | Jul 1986 | A |
| 4601702 | Hudson | Jul 1986 | A |
| 4636201 | Ambrose et al. | Jan 1987 | A |
| 4664654 | Strauss | May 1987 | A |
| 4685903 | Cable et al. | Aug 1987 | A |
| 4695274 | Fox | Sep 1987 | A |
| 4698055 | Sealfon | Oct 1987 | A |
| 4702738 | Spencer | Oct 1987 | A |
| 4704105 | Adorjan et al. | Nov 1987 | A |
| 4710178 | Henri et al. | Dec 1987 | A |
| 4729208 | Galy et al. | Mar 1988 | A |
| 4735311 | Lowe et al. | Apr 1988 | A |
| 4737144 | Choksi | Apr 1988 | A |
| 4772272 | Mcfarland | Sep 1988 | A |
| 4810215 | Kaneko | Mar 1989 | A |
| 4810249 | Haber et al. | Mar 1989 | A |
| 4813426 | Haber et al. | Mar 1989 | A |
| 4840185 | Hernandez | Jun 1989 | A |
| 4850966 | Grau et al. | Jul 1989 | A |
| 4861341 | Woodburn | Aug 1989 | A |
| 4863434 | Bayless | Sep 1989 | A |
| 4867743 | Vaillancourt | Sep 1989 | A |
| 4874383 | Mcnaughton | Oct 1989 | A |
| 4882575 | Kawahara | Nov 1989 | A |
| 4886499 | Cirelli et al. | Dec 1989 | A |
| 4892521 | Laico et al. | Jan 1990 | A |
| 4897083 | Martell | Jan 1990 | A |
| 4900310 | Ogle, II | Feb 1990 | A |
| 4915702 | Haber | Apr 1990 | A |
| 4919569 | Wittenzellner | Apr 1990 | A |
| 4919596 | Slate et al. | Apr 1990 | A |
| 4923446 | Page et al. | May 1990 | A |
| 4929241 | Kulli | May 1990 | A |
| 4950241 | Ranford | Aug 1990 | A |
| 4950246 | Muller | Aug 1990 | A |
| 4957490 | Byrne et al. | Sep 1990 | A |
| 4964866 | Szwarc | Oct 1990 | A |
| 4994045 | Ranford | Feb 1991 | A |
| 4998924 | Ranford | Mar 1991 | A |
| 5019051 | Hake | May 1991 | A |
| 5051109 | Simon | Sep 1991 | A |
| 5062828 | Waltz | Nov 1991 | A |
| D322671 | Szwarc | Dec 1991 | S |
| 5088988 | Falonn et al. | Feb 1992 | A |
| 5109850 | Blanco et al. | May 1992 | A |
| 5112317 | Michel | May 1992 | A |
| 5114406 | Gabriel et al. | May 1992 | A |
| 5127910 | Talonn et al. | Jul 1992 | A |
| 5131816 | Brown et al. | Jul 1992 | A |
| 5147326 | Talonn et al. | Sep 1992 | A |
| 5156599 | Ranford et al. | Oct 1992 | A |
| 5190521 | Hubbard et al. | Mar 1993 | A |
| 5217437 | Talonn et al. | Jun 1993 | A |
| 5246670 | Haber et al. | Sep 1993 | A |
| 5254096 | Rondelet et al. | Oct 1993 | A |
| 5267977 | Feeney, Jr. | Dec 1993 | A |
| 5269762 | Armbruster et al. | Dec 1993 | A |
| 5275582 | Wimmer | Jan 1994 | A |
| 5282593 | Fast | Feb 1994 | A |
| 5295966 | Stern et al. | Mar 1994 | A |
| 5298023 | Haber et al. | Mar 1994 | A |
| 5300045 | Plassche, Jr. | Apr 1994 | A |
| 5318522 | D'Antonio | Jun 1994 | A |
| 5338311 | Mahurkar | Aug 1994 | A |
| 5342313 | Campbell et al. | Aug 1994 | A |
| 5348544 | Sweeney et al. | Sep 1994 | A |
| 5366498 | Brannan et al. | Nov 1994 | A |
| 5376785 | Chin | Dec 1994 | A |
| 5383865 | Michel | Jan 1995 | A |
| D356150 | Duggan et al. | Mar 1995 | S |
| 5415645 | Friend et al. | May 1995 | A |
| 5456360 | Griffin | Oct 1995 | A |
| 5478315 | Brothers et al. | Dec 1995 | A |
| 5478316 | Bitdinger et al. | Dec 1995 | A |
| 5482446 | Williamson et al. | Jan 1996 | A |
| 5496274 | Graves et al. | Mar 1996 | A |
| 5501665 | Jhuboo et al. | Mar 1996 | A |
| 5505709 | Funderburk et al. | Apr 1996 | A |
| 5562624 | Righi et al. | Oct 1996 | A |
| 5562686 | Sauer et al. | Oct 1996 | A |
| 5593390 | Castellano et al. | Jan 1997 | A |
| 5609580 | Kwiatkowski et al. | Mar 1997 | A |
| 5611785 | Mito et al. | Mar 1997 | A |
| 5616132 | Newman | Apr 1997 | A |
| 5624400 | Firth et al. | Apr 1997 | A |
| 5637095 | Nason et al. | Jun 1997 | A |
| 5643218 | Lynn et al. | Jul 1997 | A |
| 5645530 | Boukhny et al. | Jul 1997 | A |
| 5645955 | Maglica | Jul 1997 | A |
| 5647853 | Feldmann et al. | Jul 1997 | A |
| 5658256 | Shields | Aug 1997 | A |
| 5662678 | Macklin | Sep 1997 | A |
| 5672160 | Oesterlind et al. | Sep 1997 | A |
| 5690618 | Smith et al. | Nov 1997 | A |
| 5697908 | Imbert et al. | Dec 1997 | A |
| 5697916 | Schraga | Dec 1997 | A |
| 5725500 | Micheler | Mar 1998 | A |
| 5728075 | Levander | Mar 1998 | A |
| D393314 | Meisner et al. | Apr 1998 | S |
| 5741275 | Wyssmann | Apr 1998 | A |
| 5766186 | Faraz et al. | Jun 1998 | A |
| 5776103 | Kriesel et al. | Jul 1998 | A |
| 5795675 | Maglica | Aug 1998 | A |
| 5800420 | Gross et al. | Sep 1998 | A |
| 5807375 | Gross et al. | Sep 1998 | A |
| 5810167 | Fujii | Sep 1998 | A |
| 5810784 | Tamaro | Sep 1998 | A |
| 5814020 | Gross | Sep 1998 | A |
| 5830187 | Kriesel et al. | Nov 1998 | A |
| 5836920 | Robertson | Nov 1998 | A |
| 5848991 | Gross et al. | Dec 1998 | A |
| 5851197 | Marano et al. | Dec 1998 | A |
| 5858001 | Tsals et al. | Jan 1999 | A |
| 5858008 | Capaccio | Jan 1999 | A |
| 5868710 | Battiato et al. | Feb 1999 | A |
| 5893842 | Imbert | Apr 1999 | A |
| 5894015 | Rechtin | Apr 1999 | A |
| 5919167 | Mulhauser et al. | Jul 1999 | A |
| 5926596 | Edwards et al. | Jul 1999 | A |
| 5931814 | Alex et al. | Aug 1999 | A |
| 5941850 | Shah et al. | Aug 1999 | A |
| 5944699 | Barrelle et al. | Aug 1999 | A |
| 5948392 | Haslwanter et al. | Sep 1999 | A |
| 5954697 | Srisathapat et al. | Sep 1999 | A |
| 5957895 | Sage et al. | Sep 1999 | A |
| 5968011 | Larsen et al. | Oct 1999 | A |
| 5989221 | Hjertman | Nov 1999 | A |
| 5993423 | Choi | Nov 1999 | A |
| 6004296 | Jansen et al. | Dec 1999 | A |
| 6004297 | Steenfeldt-Jensen et al. | Dec 1999 | A |
| 6033245 | Yamkovoy | Mar 2000 | A |
| 6033377 | Rasmussen et al. | Mar 2000 | A |
| 6045533 | Kriesel et al. | Apr 2000 | A |
| 6064797 | Crittendon et al. | May 2000 | A |
| 6074369 | Sage et al. | Jun 2000 | A |
| 6162197 | Mohammad | Dec 2000 | A |
| 6186979 | Dysarz | Feb 2001 | B1 |
| 6186982 | Gross et al. | Feb 2001 | B1 |
| 6189292 | Odell et al. | Feb 2001 | B1 |
| 6200289 | Hochman et al. | Mar 2001 | B1 |
| 6200296 | Dibiasi et al. | Mar 2001 | B1 |
| 6224569 | Brimhall | May 2001 | B1 |
| 6248093 | Moberg | Jun 2001 | B1 |
| 6270481 | Mason et al. | Aug 2001 | B1 |
| 6277095 | Kriesel et al. | Aug 2001 | B1 |
| 6277098 | Klitmose et al. | Aug 2001 | B1 |
| 6277099 | Strowe et al. | Aug 2001 | B1 |
| 6287283 | Ljunggreen et al. | Sep 2001 | B1 |
| 6293925 | Safabash et al. | Sep 2001 | B1 |
| 6302633 | Poe | Oct 2001 | B1 |
| 6336729 | Pavelle et al. | Jan 2002 | B1 |
| 6345968 | Shupe | Feb 2002 | B1 |
| 6377848 | Garde et al. | Apr 2002 | B1 |
| 6391005 | Lum et al. | May 2002 | B1 |
| 6423029 | Elsberry | Jul 2002 | B1 |
| D461243 | Niedospial | Aug 2002 | S |
| D465026 | May et al. | Oct 2002 | S |
| 6458102 | Mann et al. | Oct 2002 | B1 |
| 6485461 | Mason et al. | Nov 2002 | B1 |
| 6485465 | Moberg et al. | Nov 2002 | B2 |
| 6500150 | Gross et al. | Dec 2002 | B1 |
| 6503231 | Prausnitz et al. | Jan 2003 | B1 |
| 6511336 | Turek et al. | Jan 2003 | B1 |
| 6517517 | Farrugia et al. | Feb 2003 | B1 |
| D471274 | Diaz et al. | Mar 2003 | S |
| D471983 | Hippolyte et al. | Mar 2003 | S |
| 6554800 | Nezhadian et al. | Apr 2003 | B1 |
| 6558351 | Steil et al. | May 2003 | B1 |
| 6565541 | Sharp | May 2003 | B2 |
| 6589229 | Connelly et al. | Jul 2003 | B1 |
| 6595956 | Gross et al. | Jul 2003 | B1 |
| 6595960 | West et al. | Jul 2003 | B2 |
| 6645181 | Lavi et al. | Nov 2003 | B1 |
| 6652482 | Hochman | Nov 2003 | B2 |
| 6656158 | Mahoney et al. | Dec 2003 | B2 |
| 6656159 | Flaherty | Dec 2003 | B2 |
| 6659980 | Moberg et al. | Dec 2003 | B2 |
| 6673033 | Sciulli et al. | Jan 2004 | B1 |
| 6679862 | Diaz et al. | Jan 2004 | B2 |
| 6685678 | Evans et al. | Feb 2004 | B2 |
| 6689118 | Alchas et al. | Feb 2004 | B2 |
| 6699218 | Flaherty et al. | Mar 2004 | B2 |
| 6719141 | Heinz et al. | Apr 2004 | B2 |
| 6722916 | Buccinna et al. | Apr 2004 | B2 |
| 6743211 | Prausnitz et al. | Jun 2004 | B1 |
| 6749587 | Flaherty | Jun 2004 | B2 |
| 6752783 | Hung et al. | Jun 2004 | B2 |
| 6752787 | Causey et al. | Jun 2004 | B1 |
| 6767336 | Kaplan | Jul 2004 | B1 |
| 6768425 | Flaherty et al. | Jul 2004 | B2 |
| 6786890 | Preuthun et al. | Sep 2004 | B2 |
| 6800071 | Mcconnell et al. | Oct 2004 | B1 |
| 6805687 | Dextradeur et al. | Oct 2004 | B2 |
| 6824529 | Gross et al. | Nov 2004 | B2 |
| 6843782 | Gross et al. | Jan 2005 | B2 |
| 6854620 | Ramey | Feb 2005 | B2 |
| 6905298 | Haring | Jun 2005 | B1 |
| 6907679 | Yarborough et al. | Jun 2005 | B2 |
| 6908452 | Diaz et al. | Jun 2005 | B2 |
| 6960192 | Flaherty et al. | Nov 2005 | B1 |
| 6979316 | Rubin et al. | Dec 2005 | B1 |
| 6997727 | Legrady et al. | Feb 2006 | B1 |
| 7001360 | Veasey et al. | Feb 2006 | B2 |
| 7004104 | Kundus | Feb 2006 | B1 |
| 7004929 | McWethy et al. | Feb 2006 | B2 |
| 7025226 | Ramey | Apr 2006 | B2 |
| 7033338 | Vilks et al. | Apr 2006 | B2 |
| 7034223 | Fan et al. | Apr 2006 | B2 |
| 7048715 | Diaz et al. | May 2006 | B2 |
| 7060054 | Nissels | Jun 2006 | B2 |
| 7060059 | Keith et al. | Jun 2006 | B2 |
| 7066909 | Peter et al. | Jun 2006 | B1 |
| 7094221 | Veasey et al. | Aug 2006 | B2 |
| 7097637 | Triplett et al. | Aug 2006 | B2 |
| 7112187 | Karlsson | Sep 2006 | B2 |
| 7128727 | Flaherty et al. | Oct 2006 | B2 |
| 7144384 | Gorman et al. | Dec 2006 | B2 |
| D544092 | Lewis | Jun 2007 | S |
| 7225694 | Said | Jun 2007 | B2 |
| 7247149 | Beyerlein | Jul 2007 | B2 |
| 7250037 | Shermer et al. | Jul 2007 | B2 |
| 7267669 | Staunton et al. | Sep 2007 | B2 |
| RE39923 | Blom | Nov 2007 | E |
| 7291132 | Deruntz et al. | Nov 2007 | B2 |
| 7291159 | Schmelzeisen-Redeker et al. | Nov 2007 | B2 |
| 7303549 | Flaherty et al. | Dec 2007 | B2 |
| 7326194 | Zinger et al. | Feb 2008 | B2 |
| 7344385 | Chen | Mar 2008 | B2 |
| 7364570 | Gerondale et al. | Apr 2008 | B2 |
| 7377912 | Graf et al. | May 2008 | B2 |
| 7390312 | Barrelle | Jun 2008 | B2 |
| 7390314 | Stutz et al. | Jun 2008 | B2 |
| 7407493 | Cane | Aug 2008 | B2 |
| 7418880 | Smith | Sep 2008 | B1 |
| D578210 | Muta et al. | Oct 2008 | S |
| 7442186 | Blomquist | Oct 2008 | B2 |
| 7455663 | Bikovsky | Nov 2008 | B2 |
| 7465290 | Reilly | Dec 2008 | B2 |
| 7468055 | Prais et al. | Dec 2008 | B2 |
| 7488181 | Van | Feb 2009 | B2 |
| 7497842 | Diaz et al. | Mar 2009 | B2 |
| 7500963 | Westbye et al. | Mar 2009 | B2 |
| 7501587 | English | Mar 2009 | B2 |
| 7503786 | Kato et al. | Mar 2009 | B2 |
| 7530964 | Lavi et al. | May 2009 | B2 |
| 7540858 | Dibiasi | Jun 2009 | B2 |
| 7547281 | Hayes et al. | Jun 2009 | B2 |
| 7565208 | Harris et al. | Jul 2009 | B2 |
| 7569050 | Moberg et al. | Aug 2009 | B2 |
| D600341 | Loerwald | Sep 2009 | S |
| 7585287 | Bresina et al. | Sep 2009 | B2 |
| 7588559 | Aravena et al. | Sep 2009 | B2 |
| 7589974 | Grady et al. | Sep 2009 | B2 |
| D602155 | Foley et al. | Oct 2009 | S |
| D602586 | Foley et al. | Oct 2009 | S |
| D604835 | Conley | Nov 2009 | S |
| 7611491 | Pickhard | Nov 2009 | B2 |
| 7628770 | Ethelfeld | Dec 2009 | B2 |
| 7628772 | Mcconnell et al. | Dec 2009 | B2 |
| 7628782 | Adair et al. | Dec 2009 | B2 |
| 7637891 | Wall | Dec 2009 | B2 |
| 7637899 | Woolston et al. | Dec 2009 | B2 |
| 7641649 | Moberg et al. | Jan 2010 | B2 |
| 7660627 | Mcnichols et al. | Feb 2010 | B2 |
| 7678079 | Shermer et al. | Mar 2010 | B2 |
| 7682338 | Griffin | Mar 2010 | B2 |
| 7686787 | Moberg et al. | Mar 2010 | B2 |
| 7699829 | Harris et al. | Apr 2010 | B2 |
| 7699833 | Moberg et al. | Apr 2010 | B2 |
| 7704088 | Sakamoto | Apr 2010 | B2 |
| 7704227 | Moberg et al. | Apr 2010 | B2 |
| 7704229 | Moberg et al. | Apr 2010 | B2 |
| 7704231 | Pongpairochana et al. | Apr 2010 | B2 |
| 7708717 | Estes et al. | May 2010 | B2 |
| 7713238 | Mernoe | May 2010 | B2 |
| 7713240 | Istoc et al. | May 2010 | B2 |
| 7717903 | Estes et al. | May 2010 | B2 |
| 7717913 | Novak et al. | May 2010 | B2 |
| 7722574 | Toman et al. | May 2010 | B2 |
| 7736333 | Gillespie, III | Jun 2010 | B2 |
| 7736344 | Moberg et al. | Jun 2010 | B2 |
| 7744589 | Mounce et al. | Jun 2010 | B2 |
| 7749194 | Edwards et al. | Jul 2010 | B2 |
| 7758548 | Gillespie et al. | Jul 2010 | B2 |
| 7758550 | Bollenbach et al. | Jul 2010 | B2 |
| 7766867 | Lynch et al. | Aug 2010 | B2 |
| 7776030 | Estes et al. | Aug 2010 | B2 |
| 7780637 | Jerde et al. | Aug 2010 | B2 |
| 7789857 | Moberg et al. | Sep 2010 | B2 |
| 7794426 | Briones et al. | Sep 2010 | B2 |
| 7794427 | Estes et al. | Sep 2010 | B2 |
| 7801599 | Young et al. | Sep 2010 | B2 |
| 7806868 | De et al. | Oct 2010 | B2 |
| 7828528 | Estes et al. | Nov 2010 | B2 |
| 7837659 | Bush et al. | Nov 2010 | B2 |
| 7846132 | Gravesen et al. | Dec 2010 | B2 |
| 7854723 | Hwang et al. | Dec 2010 | B2 |
| 7857131 | Vedrine | Dec 2010 | B2 |
| 7879025 | Jacobson et al. | Feb 2011 | B2 |
| 7901382 | Daily et al. | Mar 2011 | B2 |
| 7905867 | Veasey et al. | Mar 2011 | B2 |
| 7918825 | O'Connor et al. | Apr 2011 | B2 |
| 7935104 | Yodfat et al. | May 2011 | B2 |
| 7935105 | Miller et al. | May 2011 | B2 |
| 7938803 | Mernoe et al. | May 2011 | B2 |
| 7955305 | Moberg et al. | Jun 2011 | B2 |
| 7967784 | Pongpairochana et al. | Jun 2011 | B2 |
| 7967795 | Cabiri | Jun 2011 | B1 |
| 7976514 | Abry et al. | Jul 2011 | B2 |
| 7981105 | Adair et al. | Jul 2011 | B2 |
| 7988683 | Adair et al. | Aug 2011 | B2 |
| 7993300 | Nyholm et al. | Aug 2011 | B2 |
| 7993301 | Boyd et al. | Aug 2011 | B2 |
| 7998111 | Moberg et al. | Aug 2011 | B2 |
| 8002754 | Kawamura et al. | Aug 2011 | B2 |
| 8021357 | Tanaka et al. | Sep 2011 | B2 |
| 8025658 | Chong et al. | Sep 2011 | B2 |
| 8029469 | Ethelfeld | Oct 2011 | B2 |
| 8034019 | Nair et al. | Oct 2011 | B2 |
| 8038666 | Triplett et al. | Oct 2011 | B2 |
| 8057431 | Woehr et al. | Nov 2011 | B2 |
| 8057436 | Causey et al. | Nov 2011 | B2 |
| 8062253 | Nielsen et al. | Nov 2011 | B2 |
| 8062255 | Brunnberg et al. | Nov 2011 | B2 |
| 8066694 | Wagener | Nov 2011 | B2 |
| D650079 | Presta et al. | Dec 2011 | S |
| D650903 | Kosinski et al. | Dec 2011 | S |
| 8086306 | Katzman et al. | Dec 2011 | B2 |
| D652503 | Cameron et al. | Jan 2012 | S |
| 8105279 | Mernoe et al. | Jan 2012 | B2 |
| 8105293 | Pickhard | Jan 2012 | B2 |
| 8114046 | Covino et al. | Feb 2012 | B2 |
| 8114064 | Alferness et al. | Feb 2012 | B2 |
| 8114066 | Naef et al. | Feb 2012 | B2 |
| 8118781 | Knopper et al. | Feb 2012 | B2 |
| 8121603 | Zhi | Feb 2012 | B2 |
| D657462 | Siroky | Apr 2012 | S |
| 8147446 | Yodfat et al. | Apr 2012 | B2 |
| 8151169 | Bieth et al. | Apr 2012 | B2 |
| 8152764 | Istoc et al. | Apr 2012 | B2 |
| 8152770 | Reid | Apr 2012 | B2 |
| 8152779 | Cabiri | Apr 2012 | B2 |
| 8152793 | Keinaenen et al. | Apr 2012 | B2 |
| 8157693 | Waksmundzki | Apr 2012 | B2 |
| 8157769 | Cabiri | Apr 2012 | B2 |
| 8162674 | Cho et al. | Apr 2012 | B2 |
| 8162923 | Adams et al. | Apr 2012 | B2 |
| 8167841 | Teisen-Simony et al. | May 2012 | B2 |
| 8172591 | Wertz | May 2012 | B2 |
| 8172804 | Bikovsky | May 2012 | B2 |
| 8177749 | Slate et al. | May 2012 | B2 |
| 8182462 | Istoc et al. | May 2012 | B2 |
| 8197444 | Bazargan et al. | Jun 2012 | B1 |
| 8206351 | Sugimoto et al. | Jun 2012 | B2 |
| 8221356 | Enggaard et al. | Jul 2012 | B2 |
| 8267921 | Yodfat et al. | Sep 2012 | B2 |
| 8287520 | Drew et al. | Oct 2012 | B2 |
| 8292647 | Mcgrath et al. | Oct 2012 | B1 |
| 8308679 | Hanson et al. | Nov 2012 | B2 |
| 8308695 | Laiosa | Nov 2012 | B2 |
| 8323250 | Chong et al. | Dec 2012 | B2 |
| 8348898 | Cabiri | Jan 2013 | B2 |
| 8366668 | Maritan | Feb 2013 | B2 |
| 8372039 | Mernoe et al. | Feb 2013 | B2 |
| 8373421 | Lindegger et al. | Feb 2013 | B2 |
| 8409141 | Johansen et al. | Apr 2013 | B2 |
| 8409142 | Causey et al. | Apr 2013 | B2 |
| 8409143 | Lanigan et al. | Apr 2013 | B2 |
| 8409149 | Hommann et al. | Apr 2013 | B2 |
| 8414533 | Alexandersson | Apr 2013 | B2 |
| 8414557 | Istoc et al. | Apr 2013 | B2 |
| 8425468 | Weston | Apr 2013 | B2 |
| 8430847 | Mernoe et al. | Apr 2013 | B2 |
| 8465455 | Cabiri | Jun 2013 | B2 |
| 8469942 | Kow et al. | Jun 2013 | B2 |
| 8474332 | Bente et al. | Jul 2013 | B2 |
| 8475408 | Mernoe et al. | Jul 2013 | B2 |
| 8479595 | Vazquez et al. | Jul 2013 | B2 |
| 8490790 | Cocheteux et al. | Jul 2013 | B2 |
| 8495918 | Bazargan et al. | Jul 2013 | B2 |
| 8496862 | Zelkovich et al. | Jul 2013 | B2 |
| 8512287 | Cindrich et al. | Aug 2013 | B2 |
| 8512295 | Evans et al. | Aug 2013 | B2 |
| 8517987 | Istoc et al. | Aug 2013 | B2 |
| 8517992 | Jones | Aug 2013 | B2 |
| 8523803 | Favreau | Sep 2013 | B1 |
| 8551046 | Causey et al. | Oct 2013 | B2 |
| 8556856 | Bazargan et al. | Oct 2013 | B2 |
| 8562364 | Lin et al. | Oct 2013 | B2 |
| 8568361 | Yodfat et al. | Oct 2013 | B2 |
| 8574216 | Istoc et al. | Nov 2013 | B2 |
| 8603026 | Favreau | Dec 2013 | B2 |
| 8603027 | Favreau | Dec 2013 | B2 |
| 8603028 | Mudd et al. | Dec 2013 | B2 |
| 8622966 | Causey et al. | Jan 2014 | B2 |
| 8628510 | Bazargan et al. | Jan 2014 | B2 |
| 8647303 | Cowe | Feb 2014 | B2 |
| 8674288 | Hanson et al. | Mar 2014 | B2 |
| 8679060 | Mernoe et al. | Mar 2014 | B2 |
| D702834 | Norton et al. | Apr 2014 | S |
| 8690855 | Alderete et al. | Apr 2014 | B2 |
| 8708961 | Field et al. | Apr 2014 | B2 |
| 8721603 | Lundquist | May 2014 | B2 |
| 8751237 | Kubota | Jun 2014 | B2 |
| 8753326 | Chong et al. | Jun 2014 | B2 |
| 8753331 | Murphy | Jun 2014 | B2 |
| 8764707 | Moberg et al. | Jul 2014 | B2 |
| 8764723 | Chong et al. | Jul 2014 | B2 |
| 8771222 | Kanderian et al. | Jul 2014 | B2 |
| 8777896 | Starkweather et al. | Jul 2014 | B2 |
| 8777924 | Kanderian et al. | Jul 2014 | B2 |
| 8777925 | Patton | Jul 2014 | B2 |
| 8784369 | Starkweather et al. | Jul 2014 | B2 |
| 8784370 | Lebel et al. | Jul 2014 | B2 |
| 8784378 | Weinandy | Jul 2014 | B2 |
| 8790295 | Sigg et al. | Jul 2014 | B1 |
| 8795224 | Starkweather et al. | Aug 2014 | B2 |
| 8795231 | Chong et al. | Aug 2014 | B2 |
| 8795260 | Drew | Aug 2014 | B2 |
| 8801668 | Ali et al. | Aug 2014 | B2 |
| 8801679 | Iio et al. | Aug 2014 | B2 |
| 8810394 | Kalpin | Aug 2014 | B2 |
| 8814379 | Griffiths et al. | Aug 2014 | B2 |
| 8858508 | Lavi et al. | Oct 2014 | B2 |
| 8876778 | Carrel | Nov 2014 | B2 |
| 8911410 | Ekman et al. | Dec 2014 | B2 |
| 8915882 | Cabiri | Dec 2014 | B2 |
| 8915886 | Cowe | Dec 2014 | B2 |
| 8920374 | Bokelman et al. | Dec 2014 | B2 |
| 8932266 | Wozencroft | Jan 2015 | B2 |
| 8979802 | Woehr | Mar 2015 | B2 |
| 8986250 | Beebe et al. | Mar 2015 | B2 |
| 9011164 | Filman et al. | Apr 2015 | B2 |
| 9011387 | Ekman et al. | Apr 2015 | B2 |
| 9061104 | Daniel | Jun 2015 | B2 |
| 9061110 | Avery et al. | Jun 2015 | B2 |
| 9072827 | Cabiri | Jul 2015 | B2 |
| 9072845 | Hiles | Jul 2015 | B2 |
| 9089475 | Fangrow | Jul 2015 | B2 |
| 9089641 | Kavazov | Jul 2015 | B2 |
| 9138534 | Yodfat et al. | Sep 2015 | B2 |
| 9149575 | Cabiri | Oct 2015 | B2 |
| 9173997 | Gross et al. | Nov 2015 | B2 |
| 9180248 | Moberg et al. | Nov 2015 | B2 |
| 9205199 | Kemp et al. | Dec 2015 | B2 |
| D747799 | Norton et al. | Jan 2016 | S |
| 9233215 | Hourmand et al. | Jan 2016 | B2 |
| 9259532 | Cabiri | Feb 2016 | B2 |
| 9283327 | Hourmand et al. | Mar 2016 | B2 |
| 9308327 | Marshall et al. | Apr 2016 | B2 |
| 9314569 | Causey et al. | Apr 2016 | B2 |
| 9320849 | Smith et al. | Apr 2016 | B2 |
| 9345834 | Henley et al. | May 2016 | B2 |
| 9345836 | Cabiri et al. | May 2016 | B2 |
| 9350634 | Fadell | May 2016 | B2 |
| 9352090 | Brereton et al. | May 2016 | B2 |
| 9364606 | Cindrich et al. | Jun 2016 | B2 |
| 9381300 | Smith et al. | Jul 2016 | B2 |
| 9393365 | Cabiri | Jul 2016 | B2 |
| 9421323 | Cabiri et al. | Aug 2016 | B2 |
| 9421337 | Kemp et al. | Aug 2016 | B2 |
| 9427531 | Hourmand et al. | Aug 2016 | B2 |
| 9446196 | Hourmand et al. | Sep 2016 | B2 |
| 9452261 | Alon | Sep 2016 | B2 |
| 9463280 | Cabiri | Oct 2016 | B2 |
| 9463889 | Schmitz et al. | Oct 2016 | B2 |
| 9468720 | Mudd et al. | Oct 2016 | B2 |
| 9474859 | Ekman et al. | Oct 2016 | B2 |
| 9492622 | Brereton et al. | Nov 2016 | B2 |
| 9522234 | Cabiri | Dec 2016 | B2 |
| 9539384 | Servansky | Jan 2017 | B2 |
| 9539388 | Causey et al. | Jan 2017 | B2 |
| 9539757 | Ramirez et al. | Jan 2017 | B2 |
| 9572926 | Cabiri | Feb 2017 | B2 |
| 9572927 | Bruggemann et al. | Feb 2017 | B2 |
| 9579471 | Carrel et al. | Feb 2017 | B2 |
| 9610407 | Bruggemann et al. | Apr 2017 | B2 |
| 9656019 | Cabiri et al. | May 2017 | B2 |
| 9656021 | Brereton et al. | May 2017 | B2 |
| 9656025 | Bostrom et al. | May 2017 | B2 |
| 9707356 | Hourmand et al. | Jul 2017 | B2 |
| 9744306 | Cowe | Aug 2017 | B2 |
| 9775948 | Bechmann et al. | Oct 2017 | B2 |
| 9782545 | Gross et al. | Oct 2017 | B2 |
| 9789247 | Kamen et al. | Oct 2017 | B2 |
| 9814830 | Mernoe et al. | Nov 2017 | B2 |
| 9814839 | Eaton | Nov 2017 | B2 |
| 9849242 | Henley et al. | Dec 2017 | B2 |
| 9862519 | Deutschle et al. | Jan 2018 | B2 |
| 9999722 | Yodfat et al. | Jun 2018 | B2 |
| 10010681 | Koch et al. | Jul 2018 | B2 |
| 10076356 | Hadvary et al. | Sep 2018 | B2 |
| 10143794 | Lanigan et al. | Dec 2018 | B2 |
| 10149943 | Bar-El et al. | Dec 2018 | B2 |
| D838367 | Norton et al. | Jan 2019 | S |
| 10166335 | Reber et al. | Jan 2019 | B2 |
| 10207051 | Cereda et al. | Feb 2019 | B2 |
| 10227161 | Auerbach | Mar 2019 | B2 |
| 10232116 | Ekman et al. | Mar 2019 | B2 |
| 10258740 | McLoughlin et al. | Apr 2019 | B2 |
| 10376641 | Hirschel et al. | Aug 2019 | B2 |
| 10376647 | Farris et al. | Aug 2019 | B2 |
| 10434262 | Bendek et al. | Oct 2019 | B2 |
| 10576213 | Gylleby | Mar 2020 | B2 |
| 10576220 | Armes | Mar 2020 | B2 |
| 10583260 | Kemp | Mar 2020 | B2 |
| 10603430 | Shor et al. | Mar 2020 | B2 |
| 10722645 | Kamen et al. | Jul 2020 | B2 |
| 10842942 | Iibuchi et al. | Nov 2020 | B2 |
| 20010005781 | Bergens et al. | Jun 2001 | A1 |
| 20010018937 | Nemoto | Sep 2001 | A1 |
| 20010025168 | Gross et al. | Sep 2001 | A1 |
| 20010034502 | Moberg et al. | Oct 2001 | A1 |
| 20010041869 | Causey et al. | Nov 2001 | A1 |
| 20020010423 | Gross et al. | Jan 2002 | A1 |
| 20020016569 | Critchlow et al. | Feb 2002 | A1 |
| 20020029018 | Jeffrey | Mar 2002 | A1 |
| 20020040208 | Flaherty et al. | Apr 2002 | A1 |
| 20020055711 | Lavi et al. | May 2002 | A1 |
| 20020055718 | Hunt | May 2002 | A1 |
| 20020065488 | Suzuki et al. | May 2002 | A1 |
| 20020107487 | Preuthun | Aug 2002 | A1 |
| 20020123740 | Flaherty et al. | Sep 2002 | A1 |
| 20020151855 | Douglas et al. | Oct 2002 | A1 |
| 20020161332 | Ramey | Oct 2002 | A1 |
| 20020169215 | Meng | Nov 2002 | A1 |
| 20030009133 | Ramey | Jan 2003 | A1 |
| 20030014018 | Giambattista et al. | Jan 2003 | A1 |
| 20030050602 | Pettis et al. | Mar 2003 | A1 |
| 20030069518 | Daley et al. | Apr 2003 | A1 |
| 20030125671 | Aramata et al. | Jul 2003 | A1 |
| 20030135159 | Daily et al. | Jul 2003 | A1 |
| 20030160683 | Blomquist | Aug 2003 | A1 |
| 20030167039 | Moberg | Sep 2003 | A1 |
| 20030171717 | Farrugia et al. | Sep 2003 | A1 |
| 20030199825 | Flaherty et al. | Oct 2003 | A1 |
| 20030216683 | Shekalim | Nov 2003 | A1 |
| 20030236498 | Gross et al. | Dec 2003 | A1 |
| 20040000818 | Preuthun et al. | Jan 2004 | A1 |
| 20040010207 | Flaherty et al. | Jan 2004 | A1 |
| 20040049160 | Hsieh et al. | Mar 2004 | A1 |
| 20040049161 | Sheam | Mar 2004 | A1 |
| 20040082911 | Tiu et al. | Apr 2004 | A1 |
| 20040092873 | Moberg | May 2004 | A1 |
| 20040116866 | Gorman et al. | Jun 2004 | A1 |
| 20040122359 | Wenz et al. | Jun 2004 | A1 |
| 20040122369 | Schriver | Jun 2004 | A1 |
| 20040127857 | Shemesh et al. | Jul 2004 | A1 |
| 20040135078 | Mandro | Jul 2004 | A1 |
| 20040158172 | Hancock | Aug 2004 | A1 |
| 20040158205 | Savage | Aug 2004 | A1 |
| 20040186419 | Cho | Sep 2004 | A1 |
| 20040186441 | Graf et al. | Sep 2004 | A1 |
| 20040210196 | Bush et al. | Oct 2004 | A1 |
| 20040260233 | Garibotto et al. | Dec 2004 | A1 |
| 20050027255 | Lavi et al. | Feb 2005 | A1 |
| 20050033234 | Sadowski et al. | Feb 2005 | A1 |
| 20050038391 | Wittland et al. | Feb 2005 | A1 |
| 20050065466 | Vedrine | Mar 2005 | A1 |
| 20050065472 | Cindrich et al. | Mar 2005 | A1 |
| 20050071487 | Lu et al. | Mar 2005 | A1 |
| 20050113761 | Faust et al. | May 2005 | A1 |
| 20050124940 | Martin et al. | Jun 2005 | A1 |
| 20050154353 | Alheidt | Jul 2005 | A1 |
| 20050159706 | Wilkinson et al. | Jul 2005 | A1 |
| 20050171476 | Judson et al. | Aug 2005 | A1 |
| 20050171512 | Flaherty | Aug 2005 | A1 |
| 20050177136 | Miller | Aug 2005 | A1 |
| 20050197650 | Sugimoto et al. | Sep 2005 | A1 |
| 20050203461 | Flaherty et al. | Sep 2005 | A1 |
| 20050238507 | Diianni et al. | Oct 2005 | A1 |
| 20050245956 | Steinemann et al. | Nov 2005 | A1 |
| 20050283114 | Bresina et al. | Dec 2005 | A1 |
| 20060013716 | Nason et al. | Jan 2006 | A1 |
| 20060030816 | Zubry | Feb 2006 | A1 |
| 20060036216 | Rimlinger et al. | Feb 2006 | A1 |
| 20060095010 | Westbye | May 2006 | A1 |
| 20060095014 | Ethelfeld | May 2006 | A1 |
| 20060122577 | Poulsen et al. | Jun 2006 | A1 |
| 20060124269 | Miyazaki et al. | Jun 2006 | A1 |
| 20060173406 | Hayes et al. | Aug 2006 | A1 |
| 20060173439 | Thorne et al. | Aug 2006 | A1 |
| 20060184154 | Moberg et al. | Aug 2006 | A1 |
| 20060195029 | Shults et al. | Aug 2006 | A1 |
| 20060206054 | Shekalim | Sep 2006 | A1 |
| 20060206057 | Deruntz et al. | Sep 2006 | A1 |
| 20060211982 | Prestrelski et al. | Sep 2006 | A1 |
| 20060229569 | Lavi et al. | Oct 2006 | A1 |
| 20060264888 | Moberg et al. | Nov 2006 | A1 |
| 20060264889 | Moberg et al. | Nov 2006 | A1 |
| 20060264890 | Moberg et al. | Nov 2006 | A1 |
| 20060264894 | Moberg et al. | Nov 2006 | A1 |
| 20060270987 | Peter | Nov 2006 | A1 |
| 20060283465 | Nickel et al. | Dec 2006 | A1 |
| 20060293722 | Slatkine et al. | Dec 2006 | A1 |
| 20070021733 | Hansen et al. | Jan 2007 | A1 |
| 20070025879 | Vandergaw | Feb 2007 | A1 |
| 20070049865 | Radmer et al. | Mar 2007 | A1 |
| 20070073228 | Mernoe et al. | Mar 2007 | A1 |
| 20070079894 | Kraus et al. | Apr 2007 | A1 |
| 20070118405 | Campbell et al. | May 2007 | A1 |
| 20070167912 | Causey et al. | Jul 2007 | A1 |
| 20070179444 | Causey et al. | Aug 2007 | A1 |
| 20070185449 | Mernoe | Aug 2007 | A1 |
| 20070197954 | Keenan | Aug 2007 | A1 |
| 20070197968 | Pongpairochana et al. | Aug 2007 | A1 |
| 20070203454 | Shermer et al. | Aug 2007 | A1 |
| 20070233038 | Pruitt et al. | Oct 2007 | A1 |
| 20070265568 | Tsals et al. | Nov 2007 | A1 |
| 20070282269 | Carter et al. | Dec 2007 | A1 |
| 20080021439 | Brittingham et al. | Jan 2008 | A1 |
| 20080033367 | Haury et al. | Feb 2008 | A1 |
| 20080033369 | Kohlbrenner et al. | Feb 2008 | A1 |
| 20080033393 | Edwards et al. | Feb 2008 | A1 |
| 20080051711 | Mounce et al. | Feb 2008 | A1 |
| 20080051730 | Bikovsky | Feb 2008 | A1 |
| 20080059133 | Edwards et al. | Mar 2008 | A1 |
| 20080097326 | Moberg et al. | Apr 2008 | A1 |
| 20080097381 | Moberg et al. | Apr 2008 | A1 |
| 20080097387 | Spector | Apr 2008 | A1 |
| 20080108951 | Jerde et al. | May 2008 | A1 |
| 20080140006 | Eskuri et al. | Jun 2008 | A1 |
| 20080140014 | Miller et al. | Jun 2008 | A1 |
| 20080140018 | Enggaard et al. | Jun 2008 | A1 |
| 20080147004 | Mann et al. | Jun 2008 | A1 |
| 20080167641 | Hansen et al. | Jul 2008 | A1 |
| 20080188813 | Miller et al. | Aug 2008 | A1 |
| 20080208138 | Lim et al. | Aug 2008 | A1 |
| 20080215006 | Thorkild | Sep 2008 | A1 |
| 20080215013 | Felix-Faure | Sep 2008 | A1 |
| 20080215015 | Cindrich et al. | Sep 2008 | A1 |
| 20080243087 | Enggaard et al. | Oct 2008 | A1 |
| 20080249473 | Rutti et al. | Oct 2008 | A1 |
| 20080262436 | Olson | Oct 2008 | A1 |
| 20080269687 | Chong et al. | Oct 2008 | A1 |
| 20080269723 | Mastrototaro et al. | Oct 2008 | A1 |
| 20080274630 | Shelton et al. | Nov 2008 | A1 |
| 20080294143 | Tanaka et al. | Nov 2008 | A1 |
| 20080306449 | Kristensen et al. | Dec 2008 | A1 |
| 20080312601 | Cane | Dec 2008 | A1 |
| 20080319383 | Byland et al. | Dec 2008 | A1 |
| 20080319416 | Yodfat et al. | Dec 2008 | A1 |
| 20090012478 | Weston | Jan 2009 | A1 |
| 20090041805 | Walker | Feb 2009 | A1 |
| 20090048347 | Cohen et al. | Feb 2009 | A1 |
| 20090054750 | Jennewine | Feb 2009 | A1 |
| 20090069784 | Estes et al. | Mar 2009 | A1 |
| 20090076383 | Toews et al. | Mar 2009 | A1 |
| 20090076453 | Mejlhede et al. | Mar 2009 | A1 |
| 20090088694 | Carter et al. | Apr 2009 | A1 |
| 20090088731 | Campbell et al. | Apr 2009 | A1 |
| 20090093763 | Gonnelli et al. | Apr 2009 | A1 |
| 20090093792 | Gross et al. | Apr 2009 | A1 |
| 20090093793 | Gross et al. | Apr 2009 | A1 |
| 20090105650 | Wiegel et al. | Apr 2009 | A1 |
| 20090105663 | Brand et al. | Apr 2009 | A1 |
| 20090124977 | Jensen | May 2009 | A1 |
| 20090143730 | De et al. | Jun 2009 | A1 |
| 20090143735 | De et al. | Jun 2009 | A1 |
| 20090149830 | Spector | Jun 2009 | A1 |
| 20090182277 | Carter | Jul 2009 | A1 |
| 20090182284 | Morgan | Jul 2009 | A1 |
| 20090204076 | Liversidge | Aug 2009 | A1 |
| 20090209896 | Selevan | Aug 2009 | A1 |
| 20090234319 | Marksteiner | Sep 2009 | A1 |
| 20090240240 | Hines et al. | Sep 2009 | A1 |
| 20090253973 | Bashan et al. | Oct 2009 | A1 |
| 20090259176 | Yair | Oct 2009 | A1 |
| 20090281585 | Katzman et al. | Nov 2009 | A1 |
| 20090299288 | Sie et al. | Dec 2009 | A1 |
| 20090299290 | Moberg | Dec 2009 | A1 |
| 20090299397 | Ruan et al. | Dec 2009 | A1 |
| 20090326459 | Shipway et al. | Dec 2009 | A1 |
| 20090326509 | Muse et al. | Dec 2009 | A1 |
| 20100010455 | Elahi et al. | Jan 2010 | A1 |
| 20100018334 | Lessing | Jan 2010 | A1 |
| 20100030156 | Beebe et al. | Feb 2010 | A1 |
| 20100030198 | Beebe et al. | Feb 2010 | A1 |
| 20100049128 | Mckenzie et al. | Feb 2010 | A1 |
| 20100049144 | Mcconnell et al. | Feb 2010 | A1 |
| 20100057057 | Hayter et al. | Mar 2010 | A1 |
| 20100076382 | Weston | Mar 2010 | A1 |
| 20100076412 | Rush et al. | Mar 2010 | A1 |
| 20100094255 | Nycz et al. | Apr 2010 | A1 |
| 20100100076 | Rush et al. | Apr 2010 | A1 |
| 20100100077 | Rush et al. | Apr 2010 | A1 |
| 20100106098 | Atterbury et al. | Apr 2010 | A1 |
| 20100121314 | Iobbi | May 2010 | A1 |
| 20100137790 | Yodrat | Jun 2010 | A1 |
| 20100137831 | Tsais | Jun 2010 | A1 |
| 20100145303 | Yodfat et al. | Jun 2010 | A1 |
| 20100145305 | Alon | Jun 2010 | A1 |
| 20100160894 | Julian et al. | Jun 2010 | A1 |
| 20100162548 | Leidig | Jul 2010 | A1 |
| 20100168607 | Miesel | Jul 2010 | A1 |
| 20100168683 | Cabiri | Jul 2010 | A1 |
| 20100198157 | Gyrn et al. | Aug 2010 | A1 |
| 20100204657 | Yodfat et al. | Aug 2010 | A1 |
| 20100234767 | Sarstedt | Sep 2010 | A1 |
| 20100234830 | Straessler et al. | Sep 2010 | A1 |
| 20100241065 | Moberg et al. | Sep 2010 | A1 |
| 20100256486 | Savage | Oct 2010 | A1 |
| 20100264931 | Lindegger et al. | Oct 2010 | A1 |
| 20100268169 | Llewellyn-Hyde et al. | Oct 2010 | A1 |
| 20100274112 | Hoss et al. | Oct 2010 | A1 |
| 20100274192 | Mernoe | Oct 2010 | A1 |
| 20100280499 | Yodfat et al. | Nov 2010 | A1 |
| 20100331826 | Field et al. | Dec 2010 | A1 |
| 20110034900 | Yodfat et al. | Feb 2011 | A1 |
| 20110054399 | Chong et al. | Mar 2011 | A1 |
| 20110054400 | Chong et al. | Mar 2011 | A1 |
| 20110066131 | Cabiri | Mar 2011 | A1 |
| 20110092915 | Olson et al. | Apr 2011 | A1 |
| 20110112504 | Causey et al. | May 2011 | A1 |
| 20110125056 | Merchant | May 2011 | A1 |
| 20110160654 | Hanson et al. | Jun 2011 | A1 |
| 20110160666 | Hanson et al. | Jun 2011 | A1 |
| 20110160669 | Gyrn et al. | Jun 2011 | A1 |
| 20110172645 | Moga et al. | Jul 2011 | A1 |
| 20110172745 | Na et al. | Jul 2011 | A1 |
| 20110178463 | Cabiri | Jul 2011 | A1 |
| 20110178472 | Cabiri | Jul 2011 | A1 |
| 20110201998 | Pongpairochana et al. | Aug 2011 | A1 |
| 20110224616 | Slate et al. | Sep 2011 | A1 |
| 20110224646 | Yodfat et al. | Sep 2011 | A1 |
| 20110238031 | Mair et al. | Sep 2011 | A1 |
| 20110245773 | Estes et al. | Oct 2011 | A1 |
| 20110270160 | Mernoe | Nov 2011 | A1 |
| 20110282282 | Lorenzen et al. | Nov 2011 | A1 |
| 20110282296 | Harms et al. | Nov 2011 | A1 |
| 20110295205 | Kaufmann et al. | Dec 2011 | A1 |
| 20110313238 | Reichenbach et al. | Dec 2011 | A1 |
| 20110319861 | Wilk | Dec 2011 | A1 |
| 20110319919 | Curry et al. | Dec 2011 | A1 |
| 20120004602 | Hanson et al. | Jan 2012 | A1 |
| 20120010594 | Holt et al. | Jan 2012 | A1 |
| 20120022344 | Kube | Jan 2012 | A1 |
| 20120022496 | Causey et al. | Jan 2012 | A1 |
| 20120022499 | Anderson et al. | Jan 2012 | A1 |
| 20120029431 | Hwang et al. | Feb 2012 | A1 |
| 20120035546 | Cabiri | Feb 2012 | A1 |
| 20120041364 | Smith | Feb 2012 | A1 |
| 20120041387 | Brüggemann et al. | Feb 2012 | A1 |
| 20120041414 | Estes et al. | Feb 2012 | A1 |
| 20120071828 | Tojo et al. | Mar 2012 | A1 |
| 20120096953 | Bente et al. | Apr 2012 | A1 |
| 20120096954 | Vazquez et al. | Apr 2012 | A1 |
| 20120101436 | Bazargan et al. | Apr 2012 | A1 |
| 20120108933 | Liang et al. | May 2012 | A1 |
| 20120109059 | Ranalletta et al. | May 2012 | A1 |
| 20120118777 | Kakiuchi et al. | May 2012 | A1 |
| 20120123387 | Gonzalez et al. | May 2012 | A1 |
| 20120129362 | Hampo et al. | May 2012 | A1 |
| 20120160033 | Kow et al. | Jun 2012 | A1 |
| 20120165733 | Bazargan et al. | Jun 2012 | A1 |
| 20120165780 | Bazargan et al. | Jun 2012 | A1 |
| 20120172817 | Brüggemann et al. | Jul 2012 | A1 |
| 20120184917 | Bom et al. | Jul 2012 | A1 |
| 20120226234 | Bazargan et al. | Sep 2012 | A1 |
| 20120238961 | Julian et al. | Sep 2012 | A1 |
| 20120259282 | Alderete et al. | Oct 2012 | A1 |
| 20130012875 | Gross et al. | Jan 2013 | A1 |
| 20130068319 | Plumptre et al. | Mar 2013 | A1 |
| 20130085457 | Schiff et al. | Apr 2013 | A1 |
| 20130089992 | Yang | Apr 2013 | A1 |
| 20130096509 | Avery et al. | Apr 2013 | A1 |
| 20130110049 | Cronenberg et al. | May 2013 | A1 |
| 20130131589 | Mudd et al. | May 2013 | A1 |
| 20130131604 | Avery | May 2013 | A1 |
| 20130133438 | Kow et al. | May 2013 | A1 |
| 20130172808 | Gilbert | Jul 2013 | A1 |
| 20130190693 | Ekman et al. | Jul 2013 | A1 |
| 20130200549 | Felts et al. | Aug 2013 | A1 |
| 20130204187 | Avery et al. | Aug 2013 | A1 |
| 20130204191 | Cindrich et al. | Aug 2013 | A1 |
| 20130237953 | Kow et al. | Sep 2013 | A1 |
| 20130245595 | Kow et al. | Sep 2013 | A1 |
| 20130245596 | Cabiri et al. | Sep 2013 | A1 |
| 20130245604 | Kouyoumjian et al. | Sep 2013 | A1 |
| 20130253419 | Favreau | Sep 2013 | A1 |
| 20130253420 | Favreau | Sep 2013 | A1 |
| 20130253421 | Favreau | Sep 2013 | A1 |
| 20130253434 | Cabiri | Sep 2013 | A1 |
| 20130267895 | Hemmingsen | Oct 2013 | A1 |
| 20130296799 | Degtiar et al. | Nov 2013 | A1 |
| 20130296824 | Mo et al. | Nov 2013 | A1 |
| 20130304021 | Cabiri et al. | Nov 2013 | A1 |
| 20130310753 | Cabiri | Nov 2013 | A1 |
| 20130323699 | Edwards et al. | Dec 2013 | A1 |
| 20130331791 | Gross et al. | Dec 2013 | A1 |
| 20130338584 | Mounce et al. | Dec 2013 | A1 |
| 20140018735 | Causey et al. | Jan 2014 | A1 |
| 20140031747 | Ardehali | Jan 2014 | A1 |
| 20140055073 | Favreau | Feb 2014 | A1 |
| 20140055076 | Favreau | Feb 2014 | A1 |
| 20140058349 | Bazargan et al. | Feb 2014 | A1 |
| 20140083517 | Moia et al. | Mar 2014 | A1 |
| 20140094755 | Bazargan et al. | Apr 2014 | A1 |
| 20140121633 | Causey et al. | May 2014 | A1 |
| 20140128807 | Moberg et al. | May 2014 | A1 |
| 20140128835 | Moberg et al. | May 2014 | A1 |
| 20140135692 | Alderete et al. | May 2014 | A1 |
| 20140135694 | Moberg et al. | May 2014 | A1 |
| 20140142499 | Moberg et al. | May 2014 | A1 |
| 20140148784 | Anderson et al. | May 2014 | A1 |
| 20140148785 | Moberg et al. | May 2014 | A1 |
| 20140163522 | Alderete et al. | Jun 2014 | A1 |
| 20140163526 | Cabiri et al. | Jun 2014 | A1 |
| 20140171881 | Cabiri | Jun 2014 | A1 |
| 20140174223 | Gross et al. | Jun 2014 | A1 |
| 20140194819 | Maule et al. | Jul 2014 | A1 |
| 20140194854 | Tsais | Jul 2014 | A1 |
| 20140207064 | Yavorsky | Jul 2014 | A1 |
| 20140207065 | Yavorsky | Jul 2014 | A1 |
| 20140207066 | Yavorsky | Jul 2014 | A1 |
| 20140213975 | Clemente et al. | Jul 2014 | A1 |
| 20140214001 | Mortazavi | Jul 2014 | A1 |
| 20140228768 | Eggert et al. | Aug 2014 | A1 |
| 20140236087 | Alderete et al. | Aug 2014 | A1 |
| 20140243786 | Gilbert et al. | Aug 2014 | A1 |
| 20140261758 | Wlodarczyk et al. | Sep 2014 | A1 |
| 20140343503 | Holmqvist | Nov 2014 | A1 |
| 20150005703 | Hutchinson et al. | Jan 2015 | A1 |
| 20150073344 | Van Damme et al. | Mar 2015 | A1 |
| 20150088071 | Cabiri | Mar 2015 | A1 |
| 20150112278 | Ray et al. | Apr 2015 | A1 |
| 20150119798 | Gross et al. | Apr 2015 | A1 |
| 20150157806 | Knutsson | Jun 2015 | A1 |
| 20150202375 | Schabbach | Jul 2015 | A1 |
| 20150374926 | Gross et al. | Dec 2015 | A1 |
| 20160030665 | Cabiri | Feb 2016 | A1 |
| 20160051756 | Cabiri | Feb 2016 | A1 |
| 20160144117 | Chun | May 2016 | A1 |
| 20160151586 | Kemp | Jun 2016 | A1 |
| 20160175515 | Mccullough | Jun 2016 | A1 |
| 20160184512 | Marbet et al. | Jun 2016 | A1 |
| 20160193406 | Cabiri | Jul 2016 | A1 |
| 20160199590 | Schabbach et al. | Jul 2016 | A1 |
| 20160213840 | Schabbach et al. | Jul 2016 | A1 |
| 20160228652 | Cabiri et al. | Aug 2016 | A1 |
| 20160296713 | Schader et al. | Oct 2016 | A1 |
| 20160296716 | Cabiri et al. | Oct 2016 | A1 |
| 20160331900 | Wei | Nov 2016 | A1 |
| 20160346478 | Bar-El et al. | Dec 2016 | A1 |
| 20160354553 | Anderson et al. | Dec 2016 | A1 |
| 20170007774 | Brockmeier | Jan 2017 | A1 |
| 20170043092 | Murakami et al. | Feb 2017 | A1 |
| 20170058349 | Levy et al. | Mar 2017 | A1 |
| 20170175859 | Brockmeier | Jun 2017 | A1 |
| 20170246399 | Forlani | Aug 2017 | A1 |
| 20170246403 | Cowe et al. | Aug 2017 | A1 |
| 20180028765 | Waller et al. | Feb 2018 | A1 |
| 20180214637 | Kemp et al. | Aug 2018 | A1 |
| 20190022306 | Gibson et al. | Jan 2019 | A1 |
| 20190060578 | Farris et al. | Feb 2019 | A1 |
| 20190071217 | Brown et al. | Mar 2019 | A1 |
| 20190175821 | Kamen et al. | Jun 2019 | A1 |
| 20190224415 | Dugand et al. | Jul 2019 | A1 |
| 20190240417 | Hostettler et al. | Aug 2019 | A1 |
| 20190328968 | Giambattista | Oct 2019 | A1 |
| 20200009323 | Nair et al. | Jan 2020 | A1 |
| 20200215270 | Ogawa et al. | Jul 2020 | A1 |
| 20200297929 | Zhang | Sep 2020 | A1 |
| 20210138157 | Bar-El et al. | May 2021 | A1 |
| 20210220551 | Dowd et al. | Jul 2021 | A1 |
| Number | Date | Country |
|---|---|---|
| 1505535 | Jun 2004 | CN |
| 1747683 | Mar 2006 | CN |
| 1863566 | Nov 2006 | CN |
| 101090749 | Dec 2007 | CN |
| 101227943 | Jul 2008 | CN |
| 101448536 | Jun 2009 | CN |
| 101522235 | Sep 2009 | CN |
| 101541362 | Sep 2009 | CN |
| 101641126 | Feb 2010 | CN |
| 201692438 | Jan 2011 | CN |
| 201941304 | Aug 2011 | CN |
| 102186733 | Sep 2011 | CN |
| 102378638 | Mar 2012 | CN |
| 105102025 | Nov 2015 | CN |
| 855313 | Nov 1952 | DE |
| 1064693 | Sep 1959 | DE |
| 19518807 | Dec 1995 | DE |
| 19717107 | Nov 1998 | DE |
| 0017412 | Oct 1980 | EP |
| 0222656 | May 1987 | EP |
| 0401179 | Dec 1990 | EP |
| 0925082 | Jun 1999 | EP |
| 1003581 | May 2000 | EP |
| 1124600 | Aug 2001 | EP |
| 1219312 | Jul 2002 | EP |
| 1472477 | Nov 2004 | EP |
| 1530979 | May 2005 | EP |
| 1666080 | Jun 2006 | EP |
| 1372762 | Feb 2007 | EP |
| 1974759 | Oct 2008 | EP |
| 2060606 | May 2009 | EP |
| 2140897 | Jan 2010 | EP |
| 2173413 | Apr 2010 | EP |
| 2185227 | May 2010 | EP |
| 2192935 | Jun 2010 | EP |
| 2361648 | Aug 2011 | EP |
| 2364739 | Sep 2011 | EP |
| 2393534 | Dec 2011 | EP |
| 2452708 | May 2012 | EP |
| 2498589 | Sep 2012 | EP |
| 2574355 | Apr 2013 | EP |
| 2393535 | Mar 2015 | EP |
| 2878321 | Jun 2015 | EP |
| 2886144 | Jun 2015 | EP |
| 1904130 | Mar 2016 | EP |
| 2991705 | Mar 2016 | EP |
| 3266478 | Jan 2018 | EP |
| 2819724 | Mar 2019 | EP |
| 2770136 | Apr 1999 | FR |
| 2436526 | Oct 2007 | GB |
| 62-112566 | May 1987 | JP |
| 01-172843 | Dec 1989 | JP |
| 05-062828 | Mar 1993 | JP |
| 07-194701 | Aug 1995 | JP |
| 09-505758 | Jun 1997 | JP |
| 11-507260 | Jun 1999 | JP |
| 2000-515394 | Nov 2000 | JP |
| 2001-512992 | Aug 2001 | JP |
| 2002-505601 | Feb 2002 | JP |
| 2002-507459 | Mar 2002 | JP |
| 2002-528676 | Sep 2002 | JP |
| 2003-501157 | Jan 2003 | JP |
| 2003-534061 | Nov 2003 | JP |
| 2004-501721 | Jan 2004 | JP |
| 2004-512100 | Apr 2004 | JP |
| 2003-527138 | Aug 2005 | JP |
| 2005-523127 | Aug 2005 | JP |
| 2005-527249 | Sep 2005 | JP |
| 2005-270629 | Oct 2005 | JP |
| 2006-507067 | Mar 2006 | JP |
| 2006-510450 | Mar 2006 | JP |
| 2006-525046 | Nov 2006 | JP |
| 2007-509661 | Apr 2007 | JP |
| 2007-306990 | Nov 2007 | JP |
| 2008-534131 | Aug 2008 | JP |
| 2008-220961 | Sep 2008 | JP |
| 2009-502273 | Jan 2009 | JP |
| 2009-101093 | May 2009 | JP |
| 2010-540054 | Dec 2010 | JP |
| 2010-540156 | Dec 2010 | JP |
| 2011-136153 | Jul 2011 | JP |
| 4947871 | Jun 2012 | JP |
| 2013-505433 | Feb 2013 | JP |
| 2013-517095 | May 2013 | JP |
| 2013-519473 | May 2013 | JP |
| 2013-530778 | Aug 2013 | JP |
| 2013-531520 | Aug 2013 | JP |
| 2013-531540 | Aug 2013 | JP |
| 2014-030489 | Feb 2014 | JP |
| 2014-515669 | Jul 2014 | JP |
| 2014-518743 | Aug 2014 | JP |
| 2015-514486 | May 2015 | JP |
| 2016-525428 | Aug 2016 | JP |
| 2016-530016 | Sep 2016 | JP |
| 9009202 | Aug 1990 | WO |
| 9307922 | Apr 1993 | WO |
| 9407553 | Apr 1994 | WO |
| 9415660 | Jul 1994 | WO |
| 9513838 | May 1995 | WO |
| 9609083 | Mar 1996 | WO |
| 9632975 | Oct 1996 | WO |
| 9700091 | Jan 1997 | WO |
| 9710012 | Mar 1997 | WO |
| 9721457 | Jun 1997 | WO |
| 9733638 | Sep 1997 | WO |
| 9857683 | Dec 1998 | WO |
| 9857686 | Dec 1998 | WO |
| 9929151 | Jun 1999 | WO |
| 9938554 | Aug 1999 | WO |
| 9959665 | Nov 1999 | WO |
| 0025844 | May 2000 | WO |
| 0069509 | Nov 2000 | WO |
| 0130415 | May 2001 | WO |
| 0130421 | May 2001 | WO |
| 0170304 | Sep 2001 | WO |
| 0172357 | Oct 2001 | WO |
| 0187384 | Nov 2001 | WO |
| 0189607 | Nov 2001 | WO |
| 0189613 | Nov 2001 | WO |
| 0202165 | Jan 2002 | WO |
| 0204049 | Jan 2002 | WO |
| 0234315 | May 2002 | WO |
| 0238204 | May 2002 | WO |
| 0256934 | Jul 2002 | WO |
| 02056934 | Jul 2002 | WO |
| 0272182 | Sep 2002 | WO |
| 0362672 | Jul 2003 | WO |
| 0390833 | Nov 2003 | WO |
| 2004000397 | Dec 2003 | WO |
| 2004032990 | Apr 2004 | WO |
| 2004098684 | Nov 2004 | WO |
| 2004105841 | Dec 2004 | WO |
| 2005018703 | Mar 2005 | WO |
| 2005037350 | Apr 2005 | WO |
| 2005072795 | Aug 2005 | WO |
| 2005070485 | Aug 2005 | WO |
| 2006018617 | Feb 2006 | WO |
| 2006037434 | Apr 2006 | WO |
| 2006052737 | May 2006 | WO |
| 2006069380 | Jun 2006 | WO |
| 2006102676 | Sep 2006 | WO |
| 2006104806 | Oct 2006 | WO |
| 2006121921 | Nov 2006 | WO |
| 2007017052 | Feb 2007 | WO |
| 2007051563 | May 2007 | WO |
| 2007056504 | May 2007 | WO |
| 2007066152 | Jun 2007 | WO |
| 2007073228 | Jun 2007 | WO |
| 2007119178 | Oct 2007 | WO |
| 2008001377 | Jan 2008 | WO |
| 2008014908 | Feb 2008 | WO |
| 2008057976 | May 2008 | WO |
| 2008072229 | Jun 2008 | WO |
| 2008076459 | Jun 2008 | WO |
| 2008078318 | Jul 2008 | WO |
| 2009019438 | Feb 2009 | WO |
| 2009022132 | Feb 2009 | WO |
| 2009043564 | Apr 2009 | WO |
| 2009044401 | Apr 2009 | WO |
| 2009046989 | Apr 2009 | WO |
| 2009043000 | Apr 2009 | WO |
| 2009069064 | Jun 2009 | WO |
| 2009125398 | Oct 2009 | WO |
| 2009144085 | Dec 2009 | WO |
| 2010078227 | Jul 2010 | WO |
| 2010078242 | Jul 2010 | WO |
| 2010089313 | Aug 2010 | WO |
| 2011075105 | Jun 2011 | WO |
| 2011090955 | Jul 2011 | WO |
| 2011090956 | Jul 2011 | WO |
| WO 2011101378 | Aug 2011 | WO |
| 2011110872 | Sep 2011 | WO |
| 2011124631 | Oct 2011 | WO |
| 2011129175 | Oct 2011 | WO |
| 2011131778 | Oct 2011 | WO |
| 2011131780 | Oct 2011 | WO |
| 2011131781 | Oct 2011 | WO |
| 2011133823 | Oct 2011 | WO |
| 2011156373 | Dec 2011 | WO |
| 2012003221 | Jan 2012 | WO |
| 2012032411 | Mar 2012 | WO |
| 2012040528 | Mar 2012 | WO |
| 2012145752 | Oct 2012 | WO |
| 2012160157 | Nov 2012 | WO |
| 2012168691 | Dec 2012 | WO |
| 2013036602 | Mar 2013 | WO |
| 2013058697 | Apr 2013 | WO |
| 2013115843 | Aug 2013 | WO |
| 2014132293 | Sep 2014 | WO |
| 2014179117 | Nov 2014 | WO |
| 2014179774 | Nov 2014 | WO |
| 2014194183 | Dec 2014 | WO |
| 2015048791 | Apr 2015 | WO |
| 2015048803 | Apr 2015 | WO |
| 2015078868 | Jun 2015 | WO |
| 2015091758 | Jun 2015 | WO |
| 2015091850 | Jun 2015 | WO |
| 2015114158 | Aug 2015 | WO |
| 2015114428 | Aug 2015 | WO |
| 2015118358 | Aug 2015 | WO |
| 2015163009 | Oct 2015 | WO |
| 2016087626 | Jun 2016 | WO |
| 2016087627 | Jun 2016 | WO |
| 2016141082 | Sep 2016 | WO |
| 2017022639 | Feb 2017 | WO |
| 2017161076 | Sep 2017 | WO |
| 2018222521 | Dec 2018 | WO |
| 2019224782 | Nov 2019 | WO |
| 2020120087 | Jun 2020 | WO |
| 2020193468 | Oct 2020 | WO |
| Entry |
|---|
| Definition of Monolithic. In Merriam-Webster's online dictionary. Retrieved from https://www.merriam-webster.com/dictionary/monolithic (Year: 2021). |
| Int'l Search Report and Written Opinion dated Dec. 15, 2016 in Int'l Application No. PCT/US2016/056258. |
| Office Action dated Aug. 17, 2021 in Indian Application No. 201827027625. |
| Office Action dated Mar. 10, 2015 in CN Application No. 201180006567.4. |
| Office Action dated Mar. 10, 2015 in U.S. Appl. No. 12/244,666 by Gross. |
| Office Action dated Mar. 10, 2015 in U.S. Appl. No. 13/643,470 by Alon. |
| Office Action dated Mar. 30, 2018 in U.S. Appl. No. 14/850,450 by Gross. |
| Office Action dated Mar. 31, 2015 in JP Application No. 2012-550068. |
| Office Action dated Mar. 5, 2014 in CN Application No. 200880117084.X. |
| Office Action dated May 1, 2015 in U.S. Appl. No. 14/638,525 by Filman. |
| Office Action dated May 13, 2015 in CN Application No. 201380025566.3. |
| Office Action dated May 14, 2018 in EP Application No. 088081112. |
| Office Action dated May 16, 2012 in U.S. Appl. No. 12/615,828. |
| Office Action dated May 18, 2018 in EP 14166591.9. |
| Office Action dated May 23, 2014 in U.S. Appl. No. 13/472,112 by Cabiri. |
| Office Action dated May 24, 2017 in U.S. Appl. No. 13/874,121, by Degtiar. |
| Office Action dated May 25, 2021 in Japanese Office Action 2018-538073. |
| Office Action dated May 3, 2012 in CN Application No. 200880117084.X. |
| Office Action dated May 31, 2016 in U.S. Appl. No. 14/593,051 by Gross. |
| Office Action dated May 4, 2017 in CN Application No. 2014101836665. |
| Office Action dated May 5, 2015 in CN Application No. 201180006571.0. |
| Office Action dated May 7, 2015 in JP Application No. 2012-550069. |
| Office Action dated Nov. 10, 2016 in U.S. Appl. No. 13/874,121, by Degtiar. |
| Office Action dated Nov. 13, 2017 in U.S. Appl. No. 14/193,692, by Gross. |
| Office Action dated Nov. 2, 2014 in CN Application No. 201180006571.0. |
| Office Action dated Nov. 21, 2014 in U.S. Appl. No. 13/429,840 by Cabiri. |
| Office Action dated Nov. 21, 2014 in U.S. Appl. No. 13/472,112 by Cabiri. |
| Office Action dated Nov. 25, 2016 in U.S. Appl. No. 13/874,017, by Cabiri. |
| Office Action dated Nov. 4, 2013 in EP Application No. 11 709 234.6. |
| Office Action dated Nov. 5, 2013 in JP Application No. 2010-527595. |
| Office Action dated Nov. 5, 2014 in U.S. Appl. No. 13/643,470 by Alon. |
| Office Action dated Nov. 8, 2017 in U.S. Appl. No. 13/874,121, by Degtiar. |
| Office Action dated Oct. 13, 2020 in Japanese Application No. 2018-538073. |
| Office Action dated Oct. 2, 2018 in JP Application No. 2018-535062 (Year: 2018). |
| Office Action dated Oct. 28, 2011 in U.S. Appl. No. 12/615,828. |
| Office Action dated Oct. 28, 2016 in CN Application No. 2014101783742. |
| Office Action dated Oct. 5, 2016 in U.S. Appl. No. 13/964,651, by Gross. |
| Office Action dated Oct. 6, 2017 in U.S. Appl. No. 14/861,478, by Cabiri. |
| Office Action dated Oct. 9, 2014 in U.S. Appl. No. 13/873,335. |
| Office Action dated Sep. 18, 2015 in U.S. Appl. No. 13/874,085 by Cabiri. |
| Office Action dated Sep. 2, 2010 in U.S. Appl. No. 12/244,688 by Gross. |
| Office Action dated Sep. 2, 2014 in JP Application No. 2012-550068. |
| Office Action dated Sep. 2, 2014 in JP Application No. 2012-550069. |
| Office Action dated Sep. 28, 2017 in IN Application No. 2528/DELNP/2010. |
| Office Action dated Sep. 29, 2013 in CN Application No. 201080040968.7. |
| Office Action dated Sep. 30, 2010 in U.S. Appl. No. 12/689,250, by Cabiri. |
| Office Action dated Sep. 30, 2015 in U.S. Appl. No. 13/667,739 by Cabiri. |
| Office Action dated Sep. 6, 2011 in U.S. Appl. No. 12/345,818. |
| Office Action dated Sep. 9, 2015 in U.S. Appl. No. 13/643,470 by Alon. |
| Office Action dated Feb. 20, 2015 in U.S. Appl. No. 13/521,181 by Cabiri. |
| Office Action dated Nov. 6, 2015 in U.S. Appl. No. 14/715,791 by Cabiri. |
| Office Action dated Oct. 6, 2020 in Japanese Application No. 2018-538527. |
| Partial European Search Report dated Nov. 24, 2015 in EP Application No. 14166592.7. |
| Search Report dated Oct. 14, 2016 in CN Application No. 2014101783742. |
| U.S. Appl. No. 12/559,563, filed Sep. 15, 2009. |
| U.S. Appl. No. 12/689,249, filed Jan. 19, 2010. |
| U.S. Appl. No. 12/689,250, filed Jan. 19, 2010. |
| U.S. Appl. No. 13/429,840, by Cabiri, filed Mar. 26, 2012. |
| U.S. Appl. No. 13/472,112, by Cabiri, filed May 15, 2012. |
| U.S. Appl. No. 13/521,167, by Cabiri, filed Jul. 9, 2012. |
| U.S. Appl. No. 13/521,181, by Cabiri, filed Jul. 9, 2012. |
| U.S. Appl. No. 13/643,470, by Alon, filed Oct. 25, 2012. |
| U.S. Appl. No. 13/733,516, by Cabiri, filed Jan. 3, 2013. |
| U.S. Appl. No. 13/873,335, by Filman, filed Apr. 30, 2013. |
| U.S. Appl. No. 13/874,017, by Cabiri, filed Apr. 30, 2013. |
| U.S. Appl. No. 13/874,085, by Cabiri, filed Apr. 30, 2013. |
| U.S. Appl. No. 13/874,121, by Degtiar, filed Apr. 30, 2013. |
| U.S. Appl. No. 13/892,905, by Cabiri, filed May 13, 2013. |
| U.S. Appl. No. 13/964,651, by Gross, filed Aug. 12, 2013. |
| U.S. Appl. No. 14/193,692, by Gross, filed Feb. 28, 2014. |
| U.S. Appl. No. 14/258,661, by Cabiri, filed Apr. 22, 2014. |
| U.S. Appl. No. 14/553,399, by Cabiri, filed Nov. 25, 2014. |
| U.S. Appl. No. 14/593,051, by Gross, filed Jan. 9, 2015. |
| U.S. Appl. No. 14/638,525, by Filman, filed Mar. 4, 2015. |
| U.S. Appl. No. 14/683,193, by Cabiri, filed Apr. 10, 2015. |
| U.S. Appl. No. 14/715,791, by Cabiri, filed May 19, 2015. |
| U.S. Appl. No. 14/725,009, by Bar-El, filed May 29, 2015. |
| U.S. Appl. No. 14/850,450, by Gross, filed Sep. 10, 2015. |
| U.S. Appl. No. 14/861,478, by Cabiri, filed Sep. 22, 2015. |
| U.S. Appl. No. 14/880,673, by Cabiri, filed Oct. 12, 2015. |
| U.S. Appl. No. 29/479,307, by Norton, filed Jan. 14, 2014. |
| U.S. Appl. No. 60/997,459, filed Oct. 2, 2007. |
| West Introduces the Daikyo Crystal Zenith RU Prefillable Syringe, Pharmaceutical Online, Jun. 2008, downloaded from webpage: http://www.pharmaceuticalonline.com/article.mvc/west-introduces-prefillab-le-syringe-system, Download date: Jan. 2009, original posting date: Jun. 2008, 2 pages. |
| Communication Pursuant to Rules 161 and 162 dated Apr. 6, 2018 in EP Application No. 16784688.0. |
| Copaxone(Registered), Innovative Drugs, Teva Pharmaceuticals, downloaded from webpage http://levapharm.com/copaxone/, Download date: Jan. 2009, original posting date: unknown, 3 pages. |
| Daikyo Crystal Zenith(Registered) polymer, Manufactured by Daikyo Seiko, Lid. (Jun. 25, 2008). |
| English translation of an Office Action dated Jan. 30, 2013 in GN Application No. 200880117084.X. |
| English translation of an Office Action dated Mar. 5, 2014 in ON Application No. 200880117084.X. |
| European Search Report (Partial) dated Mar. 8, 2017 in EP Application 16193157.1. |
| Extended European Search Report dated Aug. 7, 2014 in EP Application No. 14174774. |
| Extended European Search Report dated Feb. 12, 2018 in EP Application No. 17191756.0. |
| Extended European Search Report dated Feb. 13, 2017 in EP Application No. 16171626.1. |
| Extended European Search Report dated Feb. 23, 2015 in EP Application No. 14166591.9. |
| Extended European Search Report dated Feb. 23, 2015 in EP Application No. 14166596.8. |
| Extended European Search Report dated Jul. 3, 2017 in EP Application No. 16190054.3. |
| Extended European Search Report dated Mar. 27, 2014 in EP Application No. 14154717.4. |
| Extended European Search Report dated Mar. 8, 2016 in EP Application No. 14166592.7. |
| Extended European Search Report dated Nov. 10, 2016 in EP Application No. 08808111.2. |
| Extended European Search Report dated Jul. 28, 2020 in European Application No. 20172466.3. |
| Extended Search Report dated Aug. 7, 2014 in EP Application No. 14171477.4. |
| Extended Search Report dated Jul. 7, 2017 in EP Application No. 16193157.1. |
| Int'l Preliminary Report on Patentability dated Nov. 22, 2017 in Int'l Application No. PCT/US2016/068371. |
| Int'l Search Report and Written Opinion dated Jan. 12, 2011 in Int'l Application No. PCT/US2010/048556; Written Opinion. |
| Int'l Search Report and Written Opinion dated Jan. 26, 2017 in Int'l Application No. PCT/US2016/056213. |
| Int'l Search Report and Written Opinion dated Mar. 27, 2017 in Int'l Application No. PCT/US2016/056247. |
| Int'l Search Report and Written Opinion dated Apr. 21, 2017 in Int'l Application No. PCT/US2016/068367. |
| Int'l Search Report and Written Opinion dated May 15, 2017 in Int'l Application No. PCT/US2016/068371. |
| Int'l Search Report and Written Opinion dated Jul. 6, 2017 in Int'l Application No. PCT/US2017/022966. |
| Int'l Search Report and Written Opinion dated Nov. 28, 2016 in Int'l Application No. PCT/US2016/056218. |
| Int'l Search Report and Written Opinion dated Dec. 2, 2016 in Int'l Application No. PCT/US2016/056210. |
| Int'l Search Report and Written Opinion dated Dec. 5, 2016 in Int'l Application No. PCT/US2016/056233. |
| Int'l Search Report and Written Opinion dated Dec. 8, 2016 in Inl'l Application No. PCT/US2016/056227. |
| Int'l Preliminary Report on Patentability date Jan. 8, 2018 in Int'l Application No. POT/US2016/056218. |
| Int'l Preliminary Report on Patentability dated Apr. 7, 2010 in Int'l Application No. PCT/IL2008/001312. |
| Int'l Preliminary Report on Patentability dated Aug. 2, 2012 in Int'l Application No. PCT/US2011/021604. |
| Int'l Preliminary Report on Patentability dated Feb. 7, 2013 in Int'l Application No. PCT/US11/21605. |
| Int'l Preliminary Report on Patentability dated Jan. 18, 2018 in Int'l Application No. PCT/US2016/056210. |
| Int'l Preliminary Report on Patentability dated Jan. 18, 2018 in Int'l Application No. PCT/US2016/056213. |
| Int'l Preliminary Report on Patentability dated Jan. 18, 2018 in Int'l Application No. PCT/US2016/056223. |
| Int'l Preliminary Report on Patentability dated Jan. 18, 2018 in Int'l Application No. PCT/US2016/056227. |
| Int'l Preliminary Report on Patentability dated Jul. 16, 2015 in Int'l Application No. PCT/US2013/078040. |
| Int'l Preliminary Report on Patentability dated May 14, 2015 in Int'l Application No. PCT/US2013/065211. |
| Int'l Preliminary Report on Patentability dated Nov. 27, 2014 in Int'l Application No. PCT/US2013/039465. |
| Int'l Preliminary Report on Patentability dated Nov. 30, 2017 in Int'l Application No. PCT/US2016/068367. |
| Int'l Preliminary Report on Patentability dated Nov. 9, 2018 in Int'l Application No. PCT/US2016/056238. |
| Int'l Preliminary Report on Patentability dated Oct. 9, 2014 in Int'l Application No. PCT/US2013/033118. |
| Int'l Preliminary Report on Patentability dated Sep. 1, 2011 in Int'l Application No. PCT/US2010/048556. |
| Int'l Search Report and Written Opinion dated Apr. 3, 2014 in Int'l Application No. PCT/US2013/078040. |
| Int'l Search Report and Written Opinion dated Aug. 5, 2013 in Int'l Application No. PCT/US2013/033118. |
| Int'l Search Report and Written Opinion dated Jan. 7, 2014 in Int'l Application No. PCT/US2013/065211. |
| Int'l Search Report and Written Opinion dated Jul. 12, 2017 in Int'l Application No. PCT/US2016/056238. |
| Int'l Search Report and Written Opinion dated Jul. 26, 2013 in Int'l Application No. PCT/US2012/039465. |
| Int'l Search Report and Written Opinion dated Jul. 31, 2014 in Int'l Application No. PCT/US2014/033598. |
| Int'l Search Report and Written Opinion dated May 13, 2009 in Int'l Application No. PCT/IL2008/001312. |
| Int'l Search Report dated Apr. 26, 2010 in Int'l Application No. PCT/US2009/069552. |
| Int'l Search Report dated Jun. 17, 2011 in Int'l Application No. PCT/US2011/021604. |
| Int'l Search Report dated Oct. 12, 2011 in Int'l Application No. PCT/US11/21605. |
| Int'l Search Report dated Sep. 22, 2011 in Int'l Application No. PCT/IL11/00368; Written Opinion. |
| Int'l Written Opinion dated Jul. 19, 2012 in Int'l Application No. PCT/US11/21605. |
| Intel Search Report and Written Opinion dated Nov. 30, 2016 in Int'l Application No. PCT/US2016/056223. |
| International Preliminary Report on Patentability and Written Opinion dated Jul. 5, 2011 in International Application No. PCT/US2009/069552. |
| Notice of Allowance dated Aug. 24, 2015 in U.S. Appl. No. 29/479,307 by Norton. |
| Offce Action dated Sep. 21, 2010 in U.S. Appl. No. 12/244,666 by Gross. |
| Office Action dated Apr. 22, 2016 in CN Application No. 2014102892041. |
| Office Action dated Apr. 5, 2010 in U.S. Appl. No. 12/244,666 by Gross. |
| Office Action dated Apr. 5, 2010 in U.S. Appl. No. 12/244,688 by Gross. |
| Office Action dated Aug. 13, 2015 in U.S. Appl. No. 14/553,399 by Cabiri. |
| Office Action dated Aug. 14, 2017 in CN Application No. 201410178318.9. |
| Office Action dated Aug. 15, 2013 in CN Application No. 200880117084.X. |
| Office Action dated Aug. 26, 2014 in CN Application No. 201180006567.4. |
| Office Action dated Aug. 6, 2014 in EP Appl. No. 11 707 942.6. |
| Office Action dated Dec. 1, 2015 in CN Application No. 201410289204.1. |
| Office Action dated Dec. 10, 2013 in CN Application No. 201180006567.4. |
| Office Action dated Dec. 15, 2017 in U.S. Appl. No. 15/269,248, by Cabiri. |
| Office Action dated Dec. 17, 2013 in JP Application No. 2012-529808. |
| Office Action dated Dec. 4, 2017 in CN Application No. 201410178374.2. |
| Office Action dated Dec. 9, 2016 in U.S. Appl. No. 14/593,051, by Gross. |
| Office Action dated Feb. 16, 2017 in CN Application No. 2014101783189. |
| Office Action dated Feb. 21, 2012 in U.S. Appl. No. 12/689,249. |
| Office Action dated Feb. 24, 2015 in U.S. Appl. No. 14/258,661 by Cabiri. |
| Office Action dated Feb. 24, 2017 in U.S. Appl. No. 13/964,651, by Gross. |
| Office Action dated Feb. 28, 2014 in CN Application No. 201180006571.0. |
| Office Action dated Feb. 4, 2014 in EP Application No. 11 707 942.6. |
| Office Action dated Jan. 10, 2017 in U.S. Appl. No. 14/193,692, by Gross. |
| Office Action dated Jan. 30, 2013 in CN Application No. 200880117084.X. |
| Office Action dated Jan. 8, 2013 in JP Application No. 2010-527595. |
| Office Action dated Jan. 8, 2014 in U.S. Appl. No. 13/521,167 by Cabiri. |
| Office Action dated Jul. 13, 2011 in U.S. Appl. No. 12/559,563 by Cabiri. |
| Office Action dated Jul. 2, 2012 in U.S. Appl. No. 13/272,555 by Cabiri. |
| Office Action dated Jul. 28, 2020 in Japanese Application No. 2018-538074. |
| Office Action dated Jul. 3, 2017 in CN Application No. 2014101783742. |
| Office Action dated Jul. 31, 2015 in U.S. Appl. No. 13/521,181 by Cabiri. |
| Office Action dated Jul. 7, 2014 in U.S. Appl. No. 12/244,666 by Gross. |
| Office Action dated Jun. 10, 2016 in U.S. Appl. No. 13/964,651 by Gross. |
| Office Action dated Jun. 14, 2018 in U.S. Appl. No. 13/874,121, by Degtiar. |
| Office Action dated Jun. 2, 2016 in CN Application No. 2014101783189. |
| Office Action dated Jun. 3, 2014 in JP Application No. 2010-527595. |
| Office Action dated Jun. 4, 2015 in U.S. Appl. No. 13/667,739 by Cabiri. |
| Office Action dated Jun. 9, 2017 in EP Application No. 14166591.9. |
| Office Action dated Jun. 9, 2017 in EP Application No. 14166596.8. |
| Office Action dated Mar. 1, 2018 in EP Application No. 14166592.7. |
| Number | Date | Country | |
|---|---|---|---|
| 20190022323 A1 | Jan 2019 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62281536 | Jan 2016 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15204542 | Jul 2016 | US |
| Child | 16071509 | US | |
| Parent | 15269248 | Sep 2016 | US |
| Child | 15204542 | US |
